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     We have previously shown that corticosterone (CORT) can induce premature 
differentiation of somatotrophs in the chicken embryo.  CORT induction of GH mRNA is 
indirect, in that protein synthesis inhibition blocks its inducing effect.  In this study, we 
used a custom chicken microarray to analyze global gene expression in the embryonic 
pituitary gland and to identify potential direct targets of CORT that may regulate its 
induction of somatotroph differentiation.  Dispersed embryonic (e) day 11 pituitary cells 
were pretreated with cycloheximide then with CORT or treated with CORT alone for 24 
hrs.  Amplified RNA from these samples was then used on our microarray to analyze 
gene expression and in quantitative real-time PCR (qRT-PCR) analysis to determine 
relative gene expression levels.  qRT-PCR from these samples showed that GH was 
induced within 1.5 hrs and continued to significantly increase until 3 hrs.  Our microarray 
analysis revealed 25 direct early targets of CORT.  From these 25 we chose 3 genes, 
Dexras1, Ras-dva, and Prostaglandin-D Synthase to transfect into e11 pituitary cells and 
measure their effect on GH mRNA.  Neither of these genes had a direct effect on GH 
mRNA; however Dexras1 acted synergistically with CORT to induce GH mRNA.   
Dexras1 was discovered in murine AtT-20 corticotroph cells because its expression was 
rapidly induced in response to glucocorticoids. We report here a chicken Dexras1 cDNA 
that is 1631 bp in length and encodes a protein of 278 amino acid residues.  Comparison 
of the consensus chicken Dexras1 amino and nucleic acid sequence with those of human, 
mouse, and rat Dexras1 showed high homology among the species.   Expression of 
Dexras1 mRNA was detected in various tissues by Northern analysis, but was highest in 
the pituitary.  RT-PCR analysis showed expression of Dexras1 only in the pituitary.  The 
precise role of DexRas1 is unidentified at the present time; however, its distribution in a 
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CHAPTER 1:  Glucocorticoids: How they Regulate Gene Transcription 
INTRODUCTION                                                                                   
     Glucocorticoids are a class of steroid hormones that control a diversity of 
developmental, immune, metabolic, and growth functions and participate as a central 
character in basal and stress related homeostasis1-4.  In addition to their physiologic 
importance, glucocorticoids are also among the most frequently used drugs, and often 
prescribed for their anti-inflammatory and immunosuppressive properties.  The structures 
of common glucocorticoids are depicted in Figure 1.1. The vast majority of 
glucocorticoid activity in most mammals is from cortisol, also known as hydrocortisone. 
Corticosterone, the major glucocorticoid in rodents and avians, is another glucocorticoid.  
The hydroxyl group at carbon 11 of the steroid molecule is a definite necessity for 
glucocorticoid activity5.  Glucocorticoids are produced and secreted by the adrenal 
cortex.  They originally derived their name from initial studies that demonstrated their 
involvement in glucose metabolism6.  Glucocorticoids sustain and raise blood glucose by 
(1) stimulating gluconeogenesis in the liver; (2) augmenting and extending the effects of 
epinephrine and glucagons on gluconeogenesis and glycogenolysis; (3) hindering glucose 
utilization in peripheral tissues; and (4) increasing liver glycogen synthesis, hoarding 
substrate in preparation for acute responses to glycogenolytic agents such as glucagons 
and epinephrine7.   
     Synthesis and secretion of glucocorticoids by the adrenal cortex is closely tied to a 
single stimulator: adrenocorticotropic hormone (ACTH) 8, 9.  ACTH is formed as a 
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component of a large precursor called pro-opiomelanocortin (POMC) in the corticotrophs 
of the anterior pituitary10.  POMC production is stimulated by the hypothalamic peptide 









































THE GLUCOCORTICOID RECEPTOR 
     The majority of the cellular actions that are carried out by glucocorticoids are 
mediated through the interaction with the established transcription factor known as the 
glucocorticoid receptor (GR). The gene for GR was first cloned in 1985, and it encodes a 
protein 777 amino acids in length13.  It has been shown that GR is ubiquitously expressed 
and distributed, but is more prevalent in hepatic, nervous system, and muscular tissues.  
Despite being broadly dispersed, sensitivity of cells to glucocorticoids is very 
complicated and is dependent on the actions of multiple factors14.    GR is a member of a 
rather large family of proteins known as the nuclear receptors (NRs).  Thus far, 48 
nuclear receptors have been identified in humans.  In particular, based on sequence 
comparison, GR is a member of the steroid hormone receptor (SHR) subset of NRs; this 
division comprises the progesterone receptor (PR), androgen receptor (AR), the 
mineralocorticoid receptor (MR), and the estrogen receptor (ER).  As shown in Figure 
1.2, the GR like most members of the NR protein family is an assemblage of three 
smaller protein modules: the N-terminal domain (NTD), the DNA binding domain 
(DBD), and the ligand binding domain (LBD)15, 16.  These individual domains execute 
separate functions in tandem to regulate the transcriptional and signal transduction 













Figure 1.2.  The primary human GR gene is comprised of 9 exons, coding various regions 
of the receptor, such as the DNA  binding domain (DBD), ligand binding domain (LBD), 
and untranslated regions (UTR).  The presence of 3 promoters in Exon 1gives rise to 
several GH isoforms differing in the 5’-UTR.  Alternative splicing of Exon 9 generates 
mRNAs coding for hGRα and hGRβ.  In addition, alternative splicing can cause the 
insertion of an additional codon (GRγ), exon skipping (GRA) or exon deletion (GRP).  
These receptor isoforms have blunted activity.  The A and B forms of both hGRα and 
hGRβ are generated from alternative translation initiation start sites, corresponding to 




N-Terminal Domain (NTD) 
     As it relates to both size and sequence homology the NTD region epitomizes the most 
capricious domain among the NRs, even between different species of the GR17, 18. The 
major function of the NTD, also called the A/B region, is in transcription activation.  It 
includes a section that regulates a constitutive transcriptional activity and is also a target 
of several interaction proteins and kinases.  In all members of the nuclear receptor 
superfamily there are at least two transcription activating domains (TADs), one of which 
is located in the A/B domain.  This amino-terminal section is referred to as the activation 
function-1 (AF-1) or TAD1 region19.  AF1 is cell and promoter specific, but its activity is 
independent of ligand binding.  It can act constitutively in the absence of the LBD, and is 
fairly active in provoking transcription from simple promoters containing similar 
glucocorticoid response elements (GREs).20  The amino terminus of GR also contains a 
PEST domain.  This name arises from the one-letter designation of the four amino acids 
prevalent in this domain: proline (P), glutamic acid (E), serine (S), and threonine (T).  
These regions manage the stability of the GR21.  Lastly, the NTD is very immunogenic 
and includes the major known sites of phosphorylation in the GR22-24.    
DNA-Binding Domain (DBD)  
     As you proceed toward the C-terminal end of the GR, the next protein module 
contains the DNA binding domain (DBD).  This area, sometimes referred to as the C 
region, is the most conserved domain among the nuclear receptors and consists of two α-
helical structures termed “zinc fingers”.25  Zinc fingers were so named because of the 
requirement for zinc as the coordinating group to stabilize these helical regions.26  The 
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DBD contains amino acids that make contact with particular bases in the GRE sequence 
to impart site specificity for GR:DNA binding. These amino acids are positioned in the 
zinc finger closest to the amino-terminal, where the “P box” is responsible for GRE 
distinction.27, 28  The second zinc finger stabilizes the DBD:GRE contacts, and has five 
amino acids that comprise the “D box” which participates in an important role in 
homodimerization at the GRE.27, 28 Additionally, a well-defined dimmer interface is 
formed as two DBD subunits bind the DNA helix in adjacent major grooves28. 
Ligand-Binding Domain (LBD) 
     The C-terminal LBD or E region is responsible for identifying and binding to steroid 
hormone ligands, chaperones and other proteins.17  Additionally, the LBD contains the 
2nd transcription activation domain (AF-2).  In contrast to AF-1, the activity of AF-2 is 
ligand-dependent, and folds as to complete binding surfaces for other proteins such as 
coactivators and corepressors via their LXXLL motifs29 30. 
Isoforms 
     Alternative splicing of the human (h) GR gene gives rise to various GR isoforms.  
When the GR was cloned back in 1985 two GR gene splicing products were detected, 
these were termed hGRα and hGRβ.  Alternative splicing of the 9th exon generates these 
two highly homologous isoforms which are identical through amino acid 72, but vary at 
their carboxy-terminus. hGRα has an additional 50 amino acids, while hGRß possesses 
an additional nonhomologous 15 amino acids31.  The α isoform of hGR is ubiquitously 
expressed in almost all human tissues and cells, and represents the classic GR that 
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operates as a ligand-dependent transcription factor. A diagram of the primary GR gene 
and the alternative splicing event that produces hGRβ and other variants is shown in 
Figure 1.2.   
     hGRβ does not bind hormone or activate gene transcription.  As a result, it was 
originally labeled as a minor gene product and perhaps even a cloning artifact.  It took the 
work of Bamberger and Oakley, 10 years later, to show that hGRβ was an endogenous 
hGR gene product and further characterized its role and expression32, 33.  Unlike hGRα, 
hGRβ is located in the nucleus in the absence of ligand.  In spite of this, it is the ability of 
hGRβ to exert a dominant negative on hGRα -mediated transactivation of gene 
expression that is most fascinating and likely physiologically important.  The latest 
investigations examining the mechanism of the dominant negative activity of hGRβ 
propose that hGRβ exerts its effect on hGRα by forming hGRαβ heterodimers that are 
incapable of binding coactivators or by competing with hGRα for combining to 
glucocorticoid receptor-interacting protein 1(GRIP-1) and other p160 coactivators34, 35. 
FROM THE CYTOPLASM TO THE NUCLEUS 
     In cellular states where ligand is absent or deficient, the preponderance of the 
glucocorticoid receptor population dwells in the cytoplasm complexed to heat shock 
proteins (hsp) forming a large multiprotein complex 36-38.  This complex consists of the 
receptor, two molecules of HSP-90, and several other proteins.  There is one model that 
proposes that binding of ligand to the receptor causes the liberation of the bound hsp.  As 
a result the nuclear localization sites within the LBD of the GR become uncovered thus 
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allowing the activated GR to translocate into the nucleus from the cytoplasm.  In spite of 
this proposed mode of action, the role of hsp is almost certainly more convoluted because 
hsp have also been associated with having an active role within the transcriptional 
complex39 and aiding transport and cytoplasmic nuclear shuttling of GR40.  One other 
corollary resulting from ligand association is the creation of both receptor hetero- or 
homodimers41.   
     Ligand binding to the GR also initiates the phosphorylation of threonine and serine 
residues in the AF-1 domain42.  Mitogen-activated protein kinase (MAPK), cyclin-
dependent kinase (Cdk), c-Jun N-terminal kinase (JNK) are examples of some kinases 
that have been shown to regulate the action of ligand-bound GR43-46.  The role of 
phosphorylation of GR is well documented, however very little facts are known bout the 
molecular relationship between phosphorylation and ligand binding. 
 
THE ACTIVATION DOMAINS 
     After moving from the cytoplasm into the nucleus, the GR is able to attach to GREs, 
and as a result the gene is either up- or down-regulated (Figure 1.3). Although binding to 
DNA is generally a necessary prerequisite for GR to activate transcription, it is clearly 
not in itself sufficient for this to occur.  Ensuing binding to GREs, GR must somehow 
regulate transcription by directly activating RNA polymerase itself or by assisting the 
binding of other proteins and the creation of a secure transcriptional complex.  As 
mentioned before, the GR is a transcription factor that is modular in structure such that a 
particular region of the GR mediates DNA binding (DBD) while another may mediate 
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binding of a co-factor (AF-1/2).  In the preponderance of cases, the AF-1/2 activation 












































Figure 1.3.  Simplified schematic of GR transactivation or transrepression 
activities.  GR typically resides in the cytoplasm with heat shock proteins (HSP 
complex) until ligand association stimulates nuclear transport.  Two of the most 
important activities of GR are (1) direct interaction with coactivators (CoA) and 
DNA response elements, such as GREs and negative GREs, to enhance or 
diminish transcription and (2) interaction with transcription factors (such as 











     The discovery of the activation domains of the GR ushered in a new era into gene 
transcription by not only GR, but other members of the NR family.  In contrast to the 
DNA binding regions, the AF-1/2 domains of the GR that are responsible for gene 
activation cannot be ascertained on the basis of a simple assay of , for example, the 
capacity to bind DNA or another protein.  More accurately, a functional assay that 
measures gene activation following DNA binding was needed.  The activation regions of 
GR and other transcription factors have been detected on the results of so-called 
“domain-swap” experiments (Figure 1.4).  In such experiments, the DNA binding region 
of one transcription factor is combined with an assortment of regions of another factor 
and the capacity to initiate transcription of a gene containing the binding site for the first 
factor is gauged.  The two independent activation domains of the GR, each able to 
produce gene activation, were discovered in this way.  
     Once the GR is activated by ligand binding, the transcription activation domains of the 
GR are now able to recruit coactivator proteins that are needed for transcription to occur.  
Many of these accessory proteins, for example Steroid receptor coactivator-1 (SRC-1),  
possess chromatin-modifying activities such as histone acetylation47.  The importance of 
histone acetylation in gene activation will be discussed later in this chapter.  SRC-1, like 
many other coactivator proteins, possess a LXXLL motif or an NR box48.  This unique 
pattern is a short, leucine-rich, amphipathic alpha-helix which allows the protein to dock 
to the ligand-bound GR.  Joining of the ligand to the GR allows the GR to assume a 
conformation that produces a shallow hypdrophobic groove that can house the leucines of 










































Figure 1.4. Domain swapping experiment, in which the activation domain of Factor 2 is 
mapped by combining different regions of Factor 2 with the DNA binding domain of 
Factor 1 and assaying the hybrid proteins for the ability to activate transcription of a gene 








THE REMODELING OF THE CHROMATIN STRUCTURE 
     The DNA inside the nucleus of the cell is strongly compressed around a protein core 
resulting in a structure called chromatin. This chromatin configuration is organized into 
nucleosomes, which are elements consisting of ~146 of bp DNA associated with an 
octamer of 2 molecules each of core histone proteins (H2A, H2B, H3, and H4).  Gene 
expression and repression is linked with alterations in chromatin structure by enzymatic 
modification of core histones49.  When genes are not being transcribed, the DNA is firmly 
compressed around these histone proteins.  This configuration prevents the binding of 
RNA polymerase II, which is one of the enzymes that is needed for the formation of 
messenger RNA. This conformation of the chromatin structure is described as closed and 
is associated with suppression of gene expression49 (Figure 1.5). 
     The stabilization of chromatin thread in the closed state is supplemented by contacts 
between the nucleosomes and linker histones such as H1. For some time now, histone H1 
has been considered a repressor of transcription.  However, recent evidence has indicated 
that it may have a positive role in transcriptional regulation50. In this more recent function 
of histone H1, it performs as a “gate” to nucleosomal DNA.  When bound to DNA, 
histone H1 inhibits the binding of transcription factors to the DNA. In order for so called 
“opening factors” to bind, histone H1 removal is required.  These opening factors, for 
example  high mobility group (HMG)B proteins, bind to the same sites as histone H1 and 
generate a nucleosomal structure that is conducive to transcription factor binding in order 
to stimulate transcription.  The phosphorylation of histone H1 may play a crucial function 









































Figure 1.5. Gene repression and activation are regulated by acetylation of core histones. 
In the inactive state, DNA is tightly coiled around histones, forming a dense nucleosomal 
structure due to electrostatic attraction between negatively charged DNA and positively 
charged lysine residues. Acetylation of histones removes this charge, allowing loosening 
of the nucleosomal structure. Histone acetylation is mediated by transcriptional 
coactivators, which have intrinsic histone acetyltransferase (HAT) activity, whereas 
repression is induced by histone deacetylases (HDACs), which reverse this acetylation, 
allowing repackaging of the nucleosomes. From Adcock et.al. 2004, The Proceedings of 




DEACETYLATION/ACETYLATION OF HISTONES AND GENE 
ACTIVATION/REPRESSION 
     The amino-terminal tails of the core histone proteins contain particular amino acid 
residues (namely arginines, serines, and lysines) that can undergo post-translational 
modifications.  These post-translational modifications include methylation, 
phosphorylation, ubiquintination, and acetylation.  All of these alterations of histones 
have been linked to the regulation of gene expression49.  Acetyl groups contain negative 
charges, consequently attachment of these molecules to histones reduces the charge on 
the histones (i.e., makes them more negative in charge) and this repels the negative 
charge of the DNA molecules.  As a result, the tightly wound DNA assumes a more open 
configuration allowing the acetylation of the ε-group on lysines reduces the charge of the 
histone residue and subsequently releases the tightly wound DNA, allowing large protein 
complexes to bind to the DNA49.  An important innovation in the role of histone 
acetylation was the experiment that demonstrated that transcriptional coactivators such as 
CREB-binding protein (CBP) and p300/CBP-associated factor contain intrinsic histone 
acetyltransferase (HAT) activity. So when transcription factors bind to DNA, this HAT 
activity is brought to the site of gene transcription.  In addition, the connection of 
coactivator and transcription factor my further augment the HAT activity of the 
coactivator50, 51.   
     The reversal of the acteylation process is associated with repression of gene 
transcription, or histone deacteylation.  Histone deacetylation is regulated by HDACs52.   
HDACs are grouped into two classes according to their homology with yeast HDACs. 
Class 1 HDACs (HDAC1, 2, 3 and 8) are the most closely related to the yeast  
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transcriptional regulator RPD3. Class II HDACs (HDAC4, 5, 6, 7, 9, and 10) share 
domains with similarity to HDA1, another deacetylase found in yeast52. Class I HDACs 
are more ubiquitously expressed than class II HDACs.  The removal of acetyl groups 
from histones causes the DNA to become more tightly wound around the histone 
proteins, this results in a more dense chromatin structure and diminishes the accessibility 
of the DNA to binding by transcription factors.   
     In spite of this, the simple model described above does not reveal the full picture. 
Under inactive conditions, less than half of the prospective lysine residues available for 
acetylation are in fact acetylated, and these residues have a fast turnover53.  This condition 
implies that even subtle changes above or below the resting level are sufficient enough to 
cause an activated chromatin state. Furthermore, this model predicts that changes in the 
"histone code" must be transformed into downstream events very quickly53, 54. The 
"histone code" applies to the varied range of histone tail post-translational modifications 
such as methylation, phosphorylation, ubiquintination, and acetylation, which are set and 
maintained by histone-modifying enzymes and contribute to coactivator recruitment and 
subsequent increases in transcription. 
GENE TRANSCRIPTION INDUCTION BY GLUCOCORTICOIDS 
     Glucocorticoids generate the cell-specific effects by activating the GR to either 
directly or indirectly control the transcription of target genes55.  It is estimated that the 
number of genes directly regulated by glucocorticoids is between 10 and 100.   However, 
many genes can be indirectly regulated though GR interaction with other transcription 
factors and coactivators.  
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     Similar to other transcription factors, activated GR increases gene transcription 
through chromatin remodeling and the recruitment of RNA polymerase II to the site of 
local DNA unwinding. GR is able to bind with CBP and other coactivator proteins, 
including SRC-1, TIF-2, p300/CBP cointegrator protein, and GRIP-1, that increase local 
HAT activity56, 57. For example, it has been shown that Dexamethasone in A549 cells 
enhances the binding of activated GR to CBP and/or associated coactivators.  The 
consequence of this action is the acetylation of H4 on lysines 5 and 16, the recruitment of 
the activated transcription complex RNA polymerase II, and finally increased gene 
transcription56.  
     The phosphorylation of Histone H1 may also play a pivotal role in GR-mediated gene 
expression58. Histone H1 can only be removed from the mouse mammary tumor virus 
(MMTV) promoter by GR only when it is in the phosphorylated form.  What's more, 
there is a so-called “refractory” state of the MMTV promoter resulting from prolonged 
exposure to glucocorticoids.  This may be explained by the fact that long exposure to 
glucocorticoids leads to dephosphorylation of histone H1. 
GENE TRANSCRIPTION REPRESSION BY GLUCOCORTICOIDS 
     In spite of the fact of the classical model of glucocorticoid action involves an increase 
in gene activation, glucocorticoids possess action that can lead to repression of gene 
transcription.  It is this gene repression characteristic of glucocorticoids that is primarily 
responsible for the anti-inflammatory actions of glucocorticoids.  Glucocorticoids exert 
their negative gene effects by either cis or trans-repression.  Cis-mechanisms involve the 
activated GR binding directly to DNA, while trans-mechanisms do not.   
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     The cis-repression by which glucocorticoids regulate gene transcription is by binding 
to negative GREs (nGREs).  The DNA sequence of nGREs is distinct from the GREs 
which activate glucocorticoid-inducible genes, although the two are related (Table 1.1).  
This has led to the suggestion that the sequence difference causes the receptor/hormone 
complex to bind to the nGRE in a configuration in which its activation domain cannot 
interact with other transcription factors to activate transcription as occurs following 
binding to the positive GRE59.  In agreement with this idea, the GR has been shown to 
bind to the nGRE in the POMC gene as a trimer rather than the dimer form which binds 
to the GRE and stimulates transcription60.  The receptor bound in this configuration to the 
nGRE can also act by preventing binding of a positive acting factor to this or an adjacent 
site, thereby preventing gene induction.  For example, the nGRE in the human 
glycoprotein hormone alpha subunit gene, which overlaps a cyclic AMP response 
element (CRE), is only able to inhibit gene expression when the CRE is left intact61.  
Hence, it is likely that receptor bound at the negative element prevents binding of a 
transcriptional activator to the CRE and thereby inhibits gene expression. 
Binding site for positive 
regulation 
RGRACANNNTGTYCY 
Binding site for negative 
regulation 
ATYACANNNTGATCW 
Table 1.1.  Relationship of the sites in DNA which mediate gene activation or repression 
by binding the glucocorticoid receptor.  Note that the sites are related but distinct. 
 
     Trans-repression by glucocorticoids can inhibit transcription thru competition with 
other transcription factors for co-activator proteins.  It has been known for some time that 
glucocorticoids are potent inhibitors of the induction of the collagenase gene by phorbol 
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esters, owing to their anti-inflammatory effects.  This inhibition is mediated by the GR 
which inhibits the activity of the Jun and Fos proteins that normally activate the 
collagenase gene via the AP-1 sites in its promoter.  However, the collagenase promoter 
does not contain any binding sites for GR adjacent to its AP-1 sites, nor does the GR bind 
to the collagenase promoter.  Interestingly, like the GR, the Fos/Jun complex requires the 
CREB binding protein (CBP) as a co-activator to activate transcription of the collagenase 
gene.  Hence, the GR may compete with Fox/Jun for the limited quantities of the CBP co-
activator which are present in the cell62.  However, De Bosscher and colleagues have cast 
doubt on this hypothesis, showing that overexpression of CBP and other cofactors did not 
affect the glucocorticoid-concentration response curve63.  It was thought for a while that 
trans-repression by glucocorticoids involved preventing nuclear translocation of other 
transcription factors, it appears this is not the case.  Recent data suggests that 
glucocorticoids affect only steps downstream of transcription factor binding, such as 
recruitment of HDACs to the transcription initiation complex, the inhibition of the HAT 
activity of co-activators such as CBP, and preventing P-TEFb phosphorylation of RNA 
























Figure 1.6. How glucocorticoids switch off inflammatory gene expression. Many 
inflammatory genes are activated by stimuli, such as interleukin (IL)-1ß or tumor 
necrosis factor (TNF)-α, and activate NF-κB, which translocates to the nucleus. NF-κB 
binds to specific κB recognition sites in the promoter regions of responsive genes and 
subsequently recruits transcriptional coactivators, such as CBP or p300/CBP-associated 
factor, that have intrinsic HAT activity. This results in acetylation of lysines in core 
histones, leading to recruitment of large protein complexes, including RNA polymerase II 
(RNA pol II), and in turn leading to increased transcription of inflammatory genes (txn). 
Glucocorticoid receptors translocate to the nucleus after activation by corticosteroids and 
act as monomers, reducing histone acetylation. The activated GR monomer interacts with 
and inhibits the HAT activity of coactivator complexes. In addition, the GR is able to 
recruit HDAC to the NF-κB complex, leading to suppression of inflammatory genes (no 
txn). Furthermore, the GR may also be able to reduce phosphorylation of serine 2 
residues within the C-terminal repeat region of RNA polymerase II, reducing its capacity 





NONGENOMIC ACTION OF GLUCOCORTICOIDS 
     From the initial examinations on the actions of glucocorticoids, it became evident that 
steroid hormones can evoke cellular effects that occur in a very short amount of time, 
within minutes or even seconds of their treatment. These rapid actions do not conform to 
the classical "genomic" model of steroid action. Glucocorticoids effects on mRNA 
stability can be also included in the classical mode of action, because they affect gene 
expression and may be sensitive to protein synthesis inhibitors. To distinguish between 
the genomic and nongenomic effects of glucocorticoids, the definition recently given by  
Lösel and Wehling is very useful66.  According to them, nongenomic effects can be "Any 
action that does not directly and initially influence gene expression, but rather drives 
more rapid effects such as the activation of signaling cascades". This definition illustrates 
the fact that the difference between the two modes of action is not black and white. 
However, the nongenomic effects of glucocorticoids do have some distinguishing 
characteristics. In addition to the short time frame in which the effects occur, these 
characteristics include: (1) a different pharmacologic profile, because the effects are 
insensitive to transcriptional and protein synthesis inhibitors; (2) action on nonnucleated 
cells, such as platelets, erythrocytes, and spermatozoa; and (3) the ability of steroid 
analogs (such as bovine serum albumin-conjugated steroid molecules) that cannot access 
the intracellular compartment to elicit a response67.  
     A categorization of the rapid steroid effects has recently been proposed68. The 
mechanisms of action, with different specificity according to the cell type and the steroid 
studied, are frequently mediated by the production of a variety of second-messenger 
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systems, by the activation of different kinase pathways, and by alterations in ion fluxes67. 
In several of the studies, the rapid effects were shown to be regulated by the classical GR.  
In these examinations, the effects were highly sensitive to the action of nuclear receptor 
antagonists.  However, some of the nongenomic effects appear to be nuclear antagonist–
independent.  This finding implies that a different, membrane-bound GR mediates the 
nongenomic action69, 70.These receptors were originally described in amphibians, but 
have subsequently been depicted in mammalian cells.  These receptors have very unique 
hormone binding properties compared the classical cytoplasmic receptor.  They are also 
associated with a variety of intracellular signaling pathways that act thru G-protein 
coupled receptors and kinase pathways69-72. 
     A certain number of the nongenomic effects of steroids appear to be controlled by 
alterations in the physicochemical properties of the cell membrane, without the 
involvement of the GR. Due to their highly lipophilic nature, steroids can easily diffuse 
though the plasma membrane of cells, where they are believed to interfere with the 
function of membrane-bound molecules, such as ion channels or receptors. These effects 
have been observed in vitro in several cell types73.  However, in the preponderance of the 
studies concentrations that were required to achieve these effects in vitro were above 
those of physiologic and therapeutic ranges (> 10  μM)74.   Therefore, their relevance in 
vivo is questionable.  
    Some of the nongenomic effects of glucocorticoids are characterized by their action 
through the classical GR.  For example, the effect of glucocorticoids on the activation of 
endothelial nitric oxide synthase (eNOS).  Glucocorticoids have been shown to have 
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some acute cardioprotective effects on cardiac ischemia75, and nitric oxide is a key 
mediator of cardiovascular protection76. Therapeutic concentrations of dexamethasone 
activated eNOS production in human endothelial cells within 10 minutes and up to 24 
hours after stimulation77. When the cells were pretreated with the GR-antagonist RU486, 
Glucocorticoid-induced early eNOS activity and nitric oxide production were eliminated.  
However, the activity was not affected by treatment with actinomycin D.  These results 
suggest a GR-dependent and transcription-independent action. In addition, this response 
was significantly suppressed by specific inhibitors of phosphatidyl inositol 3-kinase 
(PI3K), as well as by a specific inhibitor of eNOS. In contrast, it took at least 4 hours for 
the same concentration of dexamethasone to activate the transcription of a reporter 
construct driven by multiple glucocorticoid response elements, an effect that was 
sensitive to RU486 and actinomycin D but insensitive to PI3K inhibitors. The authors 
concluded that eNOS activation by dexamethasone involves rapid, nontranscriptional 
mechanisms.  
     Two candidates for a membrane-associated glucocorticoid (GC) receptor have been so 
far studied.  The first is a 63-kD acidic glycoprotein, which has been identified in 
neuronal plasma membranes of the amphibian Taricha granulosa. It has been functionally 
characterized as a putative membrane receptor for GC, with pharmacologic characteristics 
completely distinct from the known GR78. The second candidate has been classified in 
mammalian cells as an altered form of the classical GR, which has been hypothesized to 
function as a membrane-bound glucocorticoid receptor (mGR)79. Several studies have 
characterized differences between the GR and mGR (cell localization, molecular size, and 
specificity to glucocorticoid) while these same studies have also highlighted several 
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characteristics common to both receptors, for example, shared epitope recognition for 
different antibodies directed against the GR, similar ability to bind to heat shock proteins 
or DNA, and similar phosphorylation patterns76. The existence of mGR has been 
functionally  linked to glucocorticoid-induced lysis of lymphoma cells, and it has been 
suggest to play a vital role in thymic involution and apoptosis79, 80.  
 CONCLUSION 
     The method in which glucocorticoids regulate gene transcription is in no way a simple 
model that once was believed.  For example, how can the GR interact with its GRE when 
the DNA is in the condensed conformation.  It is possible that the GR may attach to a 
GRE located within a linker DNA molecule between nucleosomes.  Or it may bind to 
GRE wrapped around histones, just as long as the core residues are facing outward81.  
Binding to the GRE can then possibly alter the local chromatin structure, allowing a 
configuration that will permit GR right of entry.  Another uncertainty that needs to be 
attended to is whether there is a particular sequence of recruitment of co-factors to the 
activated GR complex.  There has been recent work with thyroid and androgen receptors 
that showed that the nuclear receptors do not in themselves recruit all of the co-activators 
required for gene activation at target promoters82.  Lastly, it has been demonstrated that 
the stable association of GR with GRE is not required in some instances.  In some 
fascinating work by Hager and colleagues, it was shown that GR has a “hit and run” 
mechanism of action83.  They used fluorescence recovery after photobleaching and 
fluorescence loss in photobleaching to study green fluorescent protein/GR association 
with a multimer of 200 copies of stably integrated MMTV-LTR.  Their work showed that 
GR existed on DNA for less than 10 seconds before being expelled and replaced by 
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another GR.  Despite these lingering questions, progress in the basic mechanism of 
glucocorticoid-regulated gene transcription, particularly in recruitment of histone-
modying cofactors and some of the non-genomic effects, have provided researchers with 
an improved comprehension of the molecular pathways in which glucocorticoids 



















Chapter 2: Growth Hormone Gene Regulation:  A Review 
INTRODUCTION 
     Differentiation of growth hormone (GH)-secreting cells (somatotrophs) in the anterior 
lobe of the pituitary occurs during rat fetal and chick embryonic development.  The 
theory that somatotroph differentiation is regulated by glucocorticoids and thyroid 
hormones has been supported in numerous studies.  In cultures of chick embryonic and 
rat fetal pituitary cells, the differentiation of somatotrophs can be induced prematurely 
with adrenal glucocorticoids (cortisol for rat, corticosterone for chicken).  In addition, the 
GH-inducing effect of glucocorticoids can be augmented by co-treatment with thyroid 
hormones.  The plasma levels of glucocorticoids, adrenocorticotropic hormone (ACTH) 
and thyroid hormones (T3 and T4) increase during development, and during this period 
when these hormones are elevated there is a simultaneous increase in the number of 
somatotrophs.  Premature induction of somatotrophs with treatment of either 
glucocorticoids or thyroid hormones occurs in vivo as well.   Suppression of endogenous 
thyroid hormone production through the use of methimazole inhibits somatotroph 
differentiation in vivo, suggesting that endogenous thyroid hormone synthesis contributes 
to normal somatotroph differentiation. Our working model for the regulation of 
somatotroph differentiation during normal development includes modulation by elements 
of the hypothalamo–pituitary–adrenal and hypothalamo–pituitary–thyroid axes.  Further 
studies are presented in this review that characterizes the mechanism of action for these 





GROWTH HORMONE GENE STRUCTURE 
     Growth hormone (GH), a polypeptide hormone synthesized in and secreted by the 
anterior lobe of the pituitary gland, influence a vast assortment of physiological 
parameters, such as growth performance, carcass composition, and milk production84-86.  
The chicken growth hormone (cGH) gene is thought to be one of the most essential 
candidate genes that can impact chicken performance traits because of its vital function in 
growth and metabolism87, 88.  First isolated and sequenced in 198889, the cGH locus spans 
approximately 4.1 kb and encodes a 191 amino acid mature growth hormone protein and 
a 25–amino acid signal peptide. The cGH differs from its mammalian equivalent in that it 
consists of five exons and four introns90, 91 and to date only one cGH has been identified 
on chromosome 192 while in human there are 5 highly conserved GH genes93.  The 
positions of one Pit-1 binding site at –113/–104, and a suppressive thyroid hormone 
response element (TRE) at –137/–74 have been identified in the cGH promoter94.  In 
addition to Pit-1 and TRE, other regulatory elements, such as glucocorticoid response 
elements (GRE) and cAMP response element (CRE), also play an important role in the 
regulation of GH gene expression. In the rat GH gene there have been two GREs 
identified, and a mutation in the proximal element is sufficient to abolish the ability of 
mediating glucocorticoid (GC) induction of gene expression95. It has also been 
demonstrated that glucocorticoids can act synergistically with cAMP on the rainbow trout 







     Even though GH-containing cells are present in the caudal lobe of the anterior 
pituitary of early chick embryos97, these cells are unlikely to secrete GH.  Mainly because 
GH cannot be detected in the serum until embryonic 16 (e16)98.   In 1995, Porter et al. 
showed that GH-secreting somatotrophs are occasionally present on e12 and comprise a 
statistically significant proportion of the pituitary cell population on e1699.  On e16 the 
majority of somatotrophs are able to respond to GHRH, somatostatin and insulin-like 
growth factor-I (IGF-1)99-101, but the ability to respond to other GH regulating hormones, 
such as thyrotropin-releasing hormone (TRH), is hindered until later in embryonic 
development101, 102.   
     The capability of somatotrophs to differentiate, which is a post-mitotic event, does not 
happen autonomously.  Indeed, it appears to be reliant on an external signal103.  The 
serum from older embryos has the capacity to induce premature differentiation of 
somatotrophs from e12 embryos, implying that this external signal is blood borne.  As a 
matter of fact, serum for e16 embryos is more successful at inducing differentiation than 
serum from e12 embryos, and the pituitary cells from older embryos are more reactive to 
this blood borne signal103.  When serum from e16 embryos was heated or digested with 
trypsin, the ability to induce GH cells in vitro remained intact.  The potential involvement 
of a binding protein that was suppressing the somatotroph-inducing activity of e12 serum 
was revealed when parallel treatments (i.e., heating and trypsin digestion) on e12 serum 
uncovered it104. In addition, the serum bioactivity was preferentially soluble in ether, 
suggesting it was steroidal in nature. Lastly, preabsorption of e16 serum with an 
antiserum against the adrenal glucocorticoid corticosterone (CORT) suppressed the 
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capacity of the embryonic serum to induce GH cell differentiation104. The concentration 
of CORT in the circulation of chick embryos increases dramatically between e12 and 
e16105, concurrent with somatotroph differentiation. Taken together, these results indicate 
that an increase in adrenal glucocorticoid secretion of CORT during development may 
induce pituitary GH cell differentiation. 
     Glucocorticoids can stimulate the differentiation of GH cells in e12 or e14 pituitary 
cell cultures, even in the absence of GHRH104, 106.  The somatotroph inducing ability of 
e16 serum is blocked by RU486, which specifically inhibits glucocorticoid receptors in 
chickens107.  Trypsin augments the effectiveness of serum; as a result, the ontogenic 
changes in corticoid-binding proteins may also be crucial, as suggested by levels of 
serum activity following trypsin digestion between e12 and e16, which were similar104.  
CORT has been shown to be a GH-differentiation factor in vivo, in that injection of e11 
eggs with serum from e12 or e16 or with CORT itself increases the proportion of GH-
secreting cells on e14108.  The serum from e16 embryos also expands the number of GH-
containing cells108.  However, the synergistic effect of GHRH on CORT or serum-
induced somatotroph differentiation in vitro106 is not observed in vivo108. 
     Even though CORT can induce somatotroph differentiation during the 2nd trimester of 
incubation, it is ineffective during the last trimester.  CORT cannot increase the number 
of GH-cells from e17 pituitary cultures106.  GHRH by itself cannot induce somatotrophs, 
but can act synergistically with CORT to increase differentiation in e12 but not e14 
pituitary cells106.  There is actually a decrease in the number of GHRH-responsive 




     The fraction of somatotrophs responding to GHRH is about 50-70% on e1699.  In 
addition, at e16 and e18 there are more somatotrophs that respond to GHRH than to 
TRH.  Conversely, by e20, the proportions of GHRH and TRH-responsive somatotrophs 
are nearly equal (40%). These findings suggests that there is a heterogeneity in GH cell 
populations100.  These outcomes may demonstrate a delayed acquirement of TRH 
responsiveness in a single somatotroph population or it may show that there are two 
distinct somatotroph populations; one that is responsive to only one secretagogue and 
another that is responsive to both secretagogues.  As a matter of fact, early embryonic 
somatotrophs are responsive to GHRH100, while responsiveness to TRH does not happen 
until just prior to hatching102. 
     Piper and Porter in 1997 revealed that somatotroph populations may also vary in their 
responsiveness to inhibitory factors such as IGF-1 and somatostatin (SRIF)101.  Both 
SRIF and IGF-1 decreased both basal and GHRH-stimulated GH release from e16 and 
e18 embryos.  Although, only the basal number of GH cells was lowered in e20 pituitary 
cells and to a lesser extent than in earlier embryos. The elevation in GH secretion that is 
observed at hatching may reflect a reduction in sensitivity to inhibitory factors. In 
addition, Piper and Porter also noticed that IGF-1 activated a basally dormant 
somatotroph population due to the fact that treatment of e20 pituitary cells increased the 
ratio of GH secretors. 
     Lastly, there may be other factors that are required for somatotroph differentiation 
and/or maintenance.  For example, the ontogenic appearance of somatotrophs that is seen 
on e12 in chickens is complemented with the entry of macrophages and other 
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hematopoietic cells into the anterior pituitary109, thus incriminating the immune system in 
GH cell development. 
EFFECTS OF OTHER HORMONES ON GLUCOCORTICOID ACTION 
     The ability of glucocorticoids to act together with other hormones in order to induce 
their cellular actions is well known, this fact is also evident in their ability to induce 
somatotroph differentiation.     GHRH is the prime hypothalamic inciter of GH secretion 
from the pituitary.  Despite the fact that GHRH alone had no direct effect on somatotroph 
number, GHRH in combination with CORT increased the number of cells that expressed 
GH mRNA and secreted GH above the number of somatotrophs induced with CORT 
alone in cultured e12 pituitary cells106, 110.  Through binding and activating the type 2 
somatostatin receptor, SRIF is able to suppress GH secretion in chickens111.  SRIF also 
lowers the secretion of GH from somatotrophs during late embryonic development101.  
The addition of SRIF to e12 pituitary cell cultures failed to affect the CORT induction of 
GH-containing cells (unpublished finding). In conclusion, GHRH can augment the CORT 
induction on somatotroph number, however SRIF appears to have no effect.   
     It appears that in addition to hypothalamic and adrenocortical hormones, thyroid 
hormones can act to regulate somatotroph abundance during embryonic development.  In 
cultures of fetal rat pituitary glands, simultaneous treatment with cortisol and T3 was able 
to increase both the number of GH cells and GH secretion above that with cortisol alone.  
However, T3 treatment by itself was unsuccessful112.   Similar observations were seen in 
chickens.  Treatment of chick embryonic pituitary cells with T3 or T4 alone had negligible 
effects on somatotroph abundance in vitro113.  On the other hand, the combination of the 
thyroid hormones and CORT was able to augmented GH cell numbers above that found 
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with CORT alone.  In one peculiar observation, higher levels of T3 (10−8 M) partially 
suppressed the induction of GH cells by CORT. This inhibitory effect of high T3 levels 
on CORT induction of GH cells was more pronounced after 6 days of treatment. Similar 
inhibitory effects of high T3 levels on CORT induced GH secretion from existing 
somatotrophs occur later in development as well114. When cultured pituitary cells were 
pretreated with the monodeiodinase inhibitor iopanoic acid, the stimulatory effect of T4 
on CORT induction of somatotrophs was ablated.  This finding implies that conversion of 
T4 to T3 within the pituitary is required for the augmented synergistic effect of T4 and 
CORT. Taken all together, these results show that glucocorticoids and thyroid hormones 
could act together to control somatotroph number.   
     As well as the exogenous effect of the thyroid hormones to augment GH cell 
differentiation, there appears to be a function for the endogenous production of thyroid 
hormone in the timing of somatotroph differentiation during normal development.   
Pregnant rats that were treated with dexamethasone in their drinking were injected with 
T3, this treatment resulted in an increase in the number of somatotrophs on e17 of fetal 
development above that found with dexamethasone alone115.  In contrast, suppression of 
endogenous thyroid hormone production by injections of the thyroid hormone synthesis 
inhibitor methimazole reduced the number of somatotrophs on fetal day 19 and 
suppressed the dexamethasone effect on day 18. Injection of T3 or T4 into the egg 
albumen of chick embryos on e9 was able to increase somatotroph cell numbers on 
e13116. As seen in the rat, suppression of endogenous thyroid synthesis through 
administration of methimazole on e9 decreased somatotroph abundance on e14. This 
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effect could be reversed by concurrent treatment with T3. In conclusion, thyroid hormone 
secretion is required for normal somatotroph ontogeny in both rats and chickens. 
    As a whole, the results that were obtained from both in vivo and in vitro examinations 
in rat and chicken embryos point to the observation that glucocorticoid and thyroid 
hormones moderate the timing of somatotroph differentiation during embryonic 
development.  The development of GH cells may also be regulated by the actions of 
GHRH.   The model depicted in Figure 2.1 shows the effects of endocrine signals on 
somatotroph differentiation in the chick embryo. In this representation, somatotroph 
differentiation occurs in reaction to elevated levels of adrenocortical production of 
CORT, which is the result of increased secretion of ACTH from the anterior pituitary. 
Levels of both CORT and ACTH have been shown to increase significantly prior to the 
increase in GH cell number during development99, 105, 116.   Injection of ACTH or CORT 
before the endogenous elevation in their levels results in an early increase in somatotroph 
abundance108, 117.  These GH cells which are induced by CORT or ACTH are most likely 
already destined to differentiate into somatotrophs, with CORT acting as the final signal 
to induce the expression of the GH gene.  Despite CORT acting the as the principal signal 
in somatotroph differentiation, its effects are co-regulated by thyroid hormones.  It has 
been shown that the synthesis of thyroid hormone is needed for normal somatotroph 
ontogeny116.  Lastly, the normal ontogeny of GH cells during development may be 
affected by hypothalamic GHRH release. While this effect has not been proved in vivo, 
simultaneous treatment with GHRH and CORT in vitro results in a further increase in GH 
cell numbers above CORT alone106, 110.  Also, somatotroph abundance is reduced in the 











Figure 2.1. Working model of the regulation of pituitary GH cell differentiation during 
chick embryonic development by adrenal corticosterone and thyroid hormones.  From 








CORT INDUCTION OF GH GENE EXPRESSION 
     The ability of glucocorticoids to increase somatotrophs prematurely during 
development in rats and chickens is well known, although the mechanism underlying 
glucocorticoid induction of GH gene expression is not as apparent. The GH inducing 
effect of CORT appears to be indirect.   When cultures of either fetal (rat) or embryonic 
(chicken) pituitary cells have been pretreated with protein synthesis inhibitors 
(puromycin in rats, cycloheximide in chickens), the CORT stimulated increase in GH 
mRNA is ablated115, 120. This finding indicated that synthesis of some intermediate 
protein(s) induces GH gene expression in response to glucocorticoids.  It was originally 
thought that this intermediate protein was Pit-1 because Pit-1 has been shown to be 
upregulated by glucocorticoids and Pit-1 could directly increase Prolactin mRNA in 
fish121.  However this is not likely the case because Pit-1 levels were not increased by 
CORT treatment122.   
     If CORT increases GH gene expression during development through the induction of  
an go-between protein, and this protein is not Pit-1 which is known to be vital for the 
expression of the GH gene123-125, then what is the identity of this protein?  At present, the 
answer to this question is the focus of several open research projects.  The GHRH 
receptor was one apparent candidate due to the fact that glucocorticoids significantly 
increase GHRH receptor expression in rat pituitary cell lines and rat fetal pituitaries in 
culture126, 127.  On the contrary, research using cultured chick embryonic pituitary cells 
does not support the hypothesis that the GHRH receptor is involved in CORT induction 
of GH mRNA.  As stated earlier, co-treatment with CORT and GHRH increases GH 
mRNA levels synergistically above those induced by CORT treatment of e12 pituitary 
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cells alone120. As well, treatment with activators of protein kinase A (PKA) and cAMP 
production increased GH mRNA levels above that with CORT alone. However, the 
treatment of these activators in the absence of CORT failed to elevate GH mRNA levels.  
In addition, inclusion of the PKA pathway inhibitor H-89 or the PKC pathway inhibitor 
calphostin C had no affect on the ability of CORT to induce GH mRNA, although H-89 
did impede the synergistic effect of GHRH and CORT on GH mRNA120.   In summary, 
these outcomes imply that CORT stimulated GH gene expression does not happen 
through induction of GHRH receptors. Nevertheless, these findings do not rule out the 
possibility of GHRH receptors having a role in the synergistic actions of CORT and 
GHRH on GH mRNA levels. In contrast to the data on the PKA and PKC pathways, 
recent studies have shown that Ras or a Ras-related enzyme may be involved. For 
example, the Ras inhibitor manumycin suppressed CORT stimulated increases in GH 
mRNA levels120.   CORT may induce GH gene expression through activation of the Ras 
signal transduction cascade. Alternatively, CORT might induce the rapid expression of 
another factor and then this unidentified factor acts in cohort with Ras to stimulate GH 
gene expression.  Additional research in this area is required.   
     There has been one piece of the puzzle of CORT induction of somatotroph 
differentiation that has been solved.  Usually, it has been thought that CORT binds to and 
functions through primarily to the glucocorticoid receptor (GR).  However, it is well 
known that glucocorticoids show a high affinity for both GR (type II) and the mineral 
corticoid (type I) receptor.   There has been recent analysis showing that CORT 
stimulation of GH mRNA occurs through the MR as well as the GR.  Pretreatment of 
cultures of chicken pituitary cells with the GR specific antagonist ZK98299 or the MR 
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antagonist spironolactone failed to block CORT induction of somatotroph differentiation 
or increases in GH mRNA128. However, combined treatment with both ZK98299 and 
spironolactone completely eliminated the CORT induction of GH mRNA and GH-
containing cells. The presence of MR within the embryonic somatotrophs induced by 
CORT was verified by dual immunofluorescence for MR and GH. Consequently, these 
findings indicate that glucocorticoids can induce somatotroph differentiation during 
development by acting through either GR or MR. Interestingly, the embryonic 
development period between e10 and e12 is when pituitary expression of MR occurs128 
and when somatotroph differentiation is responsive to CORT treatment in vivo117.   
 
CONCLUSION 
     Glucocorticoid induction of somatotrophs has been well characterized during both rat 
fetal and chick embryonic development. Glucocorticoids possess the aptitude to provoke 
somatotroph differentiation in vitro and advance GH cell ontogeny in vivo. Endogenous 
production of CORT through treatment with ACTH can also increase the number of GH 
cells. One question that remains is whether suppression of endogenous glucocorticoid 
production or ablation/antagonism of glucocorticoid receptors impedes or hinders 
somatotroph differentiation. Quite the opposite occurs when thyroid hormone synthesis is 
suppressed, as there is a decrease in the number of GH cells that initially appear, 
implying that thyroid hormones are required in normal somatotroph ontogeny. The 
identity of the unknown intermediatory protein that functions in CORT induction of GH 
mRNA during development remains to be solved.  As of right now, all that is proven is 
that this it is not Pit-1, nor the GHRH receptor, and it does not function through the PKA 
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or PKC pathways.  Identification of the intermediary protein(s) and pathways involved in 
glucorticoid induction of cGH gene expression during development is a major research 
focus in our laboratory.  As a final point, interaction between glucocorticoids and the MR 
in glucocorticoid regulation of GH production during early development and in adults 
































Chapter 3: Cloning and characterization of a chicken dexamethasone-induced ras-   
                  related 1 (Dexras1) cDNA 
 
INTRODUCTION  
     The members of the Ras protein family are small guanine nucleotide-binding factors 
that play central roles in various cellular signal transduction pathways that regulate  
processes such as apoptosis, proliferation, and cell differentiation129, 130.  Ras proteins 
serve as binary switches in signal transduction by rotating between inactive GDP-bound 
forms and active GTP-bound forms.  They can be found in almost all cell types, where 
they have critical functions in various cellular pathways, including cytoskeletal 
organization, intracellular transport, and vesicle formation131.  The mRNA levels of ras 
genes remain relatively constant in cells, however some ras proteins can be upregulated  
in response to serum growth factors132 or in cells that have become tumorigenic131.  In 
1998, Kemppainen and Behrend identified a novel mouse gene that was rapidly induced 
in a murine corticotroph cell line (AtT-20) in response to glucocorticoid treatment 
(dexamethasone, Dex)133.  This protein was named Dexamethasone-induced Ras related 
protein 1, or Dexras1.  More recently, the human homologue of Dexras1 was identified as 
a ligand-independent activator of heterotrimeric G proteins in a pheromone assay in 
yeast134 and subsequently named Activator of G protein signaling (AGS1).   
     The predicted Dexras1/AGS1 protein contains patterns that are typical of the small G-
protein Ras-superfamily, although there is the presence of an extended C-terminus 
compared to that of H-ras.  In addition to functioning as a ligand-independent activator of 
G-proteins, Dexras1/AGS1 may act to suppress G-protein signaling downstream of 
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ligand binding135, 136.  Dexras1/AGS1 was also shown to be a protein-binding partner for 
CAPON, which is a protein known to associate with neuronal nitric oxide synthase137.  
Lastly, Dexras1 might have a potential function as a mediator of glucocorticoid negative 
feedback regulation of ACTH secretion from pituitary corticotrophs.  Dexras1/AGS1 is 
abundantly expressed in the pituitary and is quickly induced (within 15 min) in response 
to glucocorticoids133, 138.  In AtT-20 cells, this induction is glucocorticoid-specific, occurs 
in a dose-dependent manner, and appears mediated at the level of gene transcription133, 
139.  What's more, the expression of a constitutively active form of Dexras1 in AtT-20 
cells suppressed cAMP-stimulated secretion of transiently expressed growth hormone, 
corroborating the perception that Dexras1/AGS1 might work to impede regulated 
endocrine secretion in corticotrophs138. 
     To date, Dexras1 has been identified in mice, rats, and humans, but not in other 
vertebrates.  Moreover, pituitary expression of Dexras1 has not been characterized during 
normal embryonic/fetal development in any species. 
     We report here the cloning and characterization of a chicken Dexras1 cDNA.  This is 
the first time that Dexras1 has been characterized in chickens or in any other avian 
species.  We show that Dexras1 expression in the chicken is pituitary-specific, regulated 
by glucocorticoids and increases at the end of embryonic development concomitant with 





MATERIAL AND METHODS 
Animals 
     All animals used were Avian x Avian chicken embryos.  All procedures with chicken 
embryos were approved by the Institutional Animal Care and Use Committee on this 
campus.  All hormones and other chemicals were purchased from Sigma (St. Louis, MO), 
unless otherwise stated.  Embryonic day 0 (e0) was defined as the day when the eggs 
were placed in a humidified incubator (G.Q.F. Manufacturing, Savannah, GA) at 37.5 C.  
The typical length of embryonic development for chickens is 21 days.   
 
Chicken Dexras1 cDNA cloning and sequencing 
     A cDNA library was produced from chicken pituitary, hypothalamic, and pineal gland 
RNA, and clones from this library were sequenced at random as described previously140.  
One clone from this library (pgp1n.pk012.a14) with limited predicted amino acid 
homology to human, mouse, and rat Dexras1 was selected for the current study.  
Oligonucleotide primers for chicken Dexras1 were designed and purchased from Sigma-
Genosys (The Woodlands, TX).  Plasmid and PCR products were sequenced in both 
directions by the University of Maryland DNA Sequencing Facility using AmpliTaq-FS 
DNA polymerase and Big Dye terminators with dITP (Perkin-Elmer/Applied 
Biosystems; Foster City, CA) and an Applied Biosystems DNA sequencer (model 3730).  
DNA sequence assembly and alignments were conducted using Vector NTI Advance 9.0 
software (Invitrogen; Carlsbad, CA) and the overlapping sequences were assembled into 
a contig.  The sequence of chicken Dexras1 (Accession# DQ516976) was compared to 
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that of human (Accession# BCO18041), mouse (Accession# BCO34166), and rat 
(Accession# AF239157) Dexras1 using the BLASTN and BLASTX programs of the 
NCBI database (http://www.ncbi.nlm.nih.gov/BLAST/).  The amino acid sequence of 
chicken Dexras1 was predicted (SIXFRAME) and the sequence alignment 
(CLUSTALW) and comparison (TEXSHADE;DRAWTREE) with those of human, 
mouse, and rat were done using the  tools within Biology Workbench maintained by the 
San Diego Super Computer Center (http://workbench.sdsc.edu/). 
 
Tissue Distribution by Northern Blot and RT-PCR 
Northern Blot Analysis 
 
Total RNA was isolated from spleen, pituitary, lung, brain, adrenal, kidney, and 
heart of juvenile chickens using the Trizol procedure according to the manufacturer’s 
protocol (Invitrogen, Carlsbad, CA). Isolated RNA was quantified using a UV 
spectrophotometer (Genequant II; Pharmacia Biotech, Piscataway, NJ). For the Northern 
Blot analysis, 10 μg of total RNA from the aforementioned tissues were separated by 
formaldehyde 1% agarose gel electrophoresis and transferred to a nylon membrane (Zeta-
Probe® Blotting Membranes, Bio-Rad, Hercules, CA) by vacuum blotting using a Bio-
Rad Model 785 Vacuum Blotter System (Hercules, CA). The membrane was crosslinked 
using a UV stratalinker (Stratagene, La Jolla, CA). The membrane was then probed with 
a 32P-labeled full-length chicken Dexras1 cDNA probe generated by PCR using the 
pgp1n.pk012.a14 plasmid and vector-specific primers. The 20 μl PCR reaction consisted 
of 2 μl of 10X PCR buffer (500 mM KCl, 100 mM Tris-HCl, 1.0% Triton-X-100, and 
dH2O), 1 μl of 25mM MgCl2, 2 μl of 1mM dNTPs (A, T, G), 2 μl of 70 μM dCTP, 1 μl 
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each of plasmid-specific primer at 0.5 μg/μl, 2 μl containing 1 pg of purified PCR 
product, 2 μl of 3.3 μM [α32P]dCTP, 1 μl of 2 U/μl Taq Polymerase, and 6 μl of nuclease-
free water. Hot start PCR was performed using a commercial thermal cycler (Techne 
Progene; Princeton, NJ). PCR thermal cycling parameters were as follows: one cycle at 
94°C for 3 min, followed by 35 cycles of 94 °C for 45 s, 52 °C for 45 s, and 72 °C for 3 
min, with a final extension at 72 °C for 7 min. The PCR product was purified by passage 
through a spin column-30 (Sigma, St. Louis, MO) according to the manufacturer’s 
protocol. Incorporation of radioactivity was determined by β-counter. Hybridization was 
performed overnight at 65 °C using PerfectHyb™ Plus 1X Hybridization Buffer (Sigma, 
St. Louis, MO). The membrane was washed twice under low stringency conditions (2X 
SSC, 0.1% SDS, room temperature) and 3 times under high stringency conditions (0.2X 
SSC, 0.1% SDS, 65 °C) and bands were visualized by phosphorimager (Molecular 
Dynamics PhosphorImager™, Amersham Biosciences, Piscataway, NJ). The membrane 
was stripped (0.02X SSC, 0.1% SDS at 90°C) and re-hybridized with a 32P-labeled 
chicken β-actin probe.  
 
Reverse transcription polymerase chain reaction (RT-PCR) analysis 
For the RT-PCR analysis, 1 μg of total RNA from the same tissues used in the 
Northern analysis was subjected to RT-PCR using an anchored oligo-dT primer.  2 μl of 
the RT reaction were then used in a 25 μl PCR reaction using 1 set of Dexras1-specific 
primers (Sense: 5’-AAGCAGCAGATCCTGGAGAC-3’, Antisense: 5’-
CAGAGTCCGTGCACAGCTTC-3’).  Genomic liver DNA (DNA) was used a negative 
control.   
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Developmental profile of Dexras1 expression 
     Embryos were removed from the incubator on e11, e14, e17, and e20.  The pituitaries 
were isolated using a dissecting microscope, immediately frozen in liquid nitrogen, then 
stored at -80 °C until RNA extraction.  5 pituitaries were pooled together for each 
replicate at each age (n=3).   
CORT  induction of Dexras1 
     Eggs were removed from the incubator on e12.  Fertile eggs were then injected into 
the small apical end with either 1500 ng (in 100 μl of 2.9% ethanol solution) of CORT or 
100 μl of 2.9% ethanol in deionized water and then immediately placed back into the 
incubator for 2 hours.   After the 2 hours, the pituitaries were isolated using a dissecting 
microscope, immediately frozen in liquid nitrogen, and then stored at -80 °C until RNA 
extraction.  5 pituitaries were pooled together for each replicate of each treatment group 
(n=3).   
RNA extraction, Reverse transcription, and Quantitative Real-time PCR (qRT-PCR) 
     Total RNA was extracted from the pituitaries using the RNeasy Mini Kit (Qiagen, 
Valencia, CA) according to the manufacturer’s protocol, and then quantified by 
measuring the absorbance at 260 and 280 nm using a UV spectrophotometer (Genequant 
II; Pharmacia Biotech, Piscataway, NJ).  1 μg of the total RNA was then reverse-
transcribed (RT) with SuperScript II (Invitrogen, Carlsbad, CA) using an oligo-dT primer 
in a 20 μl reaction.  Following reverse transcription, 2 µl of the RT reaction was used per 
25 µl of real-time PCR reaction employing SYBR green detection. Chicken Dexras1 
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specific primers (Sense: 5’ – GGTCTACCAGCTCGACATCC-3’, Antisense: 5’-
TGAACACGAGGATGAAAACG-3’) were designed using Beacon Designer 2.1 
software (Bio-Rad Laboratories).  Primers were also designed for chicken Beta-actin, 
which was used as a normalizing gene (Sense: 5’CGCATAAAACAAGACGAGA-3’, 
Antisense:5’-GTTTTTAAGGCGGAAGATACA-3’).  PCR standards were prepared for 
both Dexras1 and Beta-actin using the cDNA from one of the control groups using the 
same primers.  The PCR standards were purified using a spin column, their 
concentrations determined, and then diluted to contain 1x102 to 1x108 transcripts/µl. 
Real-time PCR was performed in a Bio-Rad iCycler using iQ SYBR Green Supermix 
(Bio-Rad Laboratories) and analyzed by iCycler iQ Real-time PCR Detection System 
Software Version 3.0 A.  The quantity of cDNA in unknown samples was calculated from 
the appropriate external standard curve run simultaneously with the samples. Samples and 
standards were assayed in duplicate. Relative expression levels were calculated with the 
following formula: number of Dexras1 transcripts/number of Beta-actin transcripts. 
 
Statistical Analysis 
     Statistical analyses were performed using Statistical Analysis System (SAS) version 
8.02 (SAS Institute, Cary, NC).  Levels of mRNA reported are the means and standard 
errors of the relative expression levels described above. Prior to statistical analysis, qRT-
PCR data were transformed to correct for heterogeneity of variance among treatment 
groups by taking the log10 of the relative expression levels. Results were then analyzed by 
analysis of variance using the PROC MIXED procedure of the Statistical Analysis 
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System (SAS; SAS Institute; Cary, NC). Differences between treatments were compared 




Sequence comparison to other species 
     We have recently isolated a chicken Dexras1 clone from a chicken neuroendocrine 
library constructed in our lab.  The cDNA encodes an open reading frame of 837 bp that 
encodes a putative chicken protein with a predicted molecular mass of approximately 
31.5 kDa.  The nucleotide and predicted amino acid sequences are available in Genbank 
(Accession# DQ516976).  Sequence analysis has shown that chicken Dexras1 is highly 
homologous at both the nucleic acid and protein level to human, mouse, and rat Dexras1 
(Table 3.1).  All motifs that are known to be vital for Ras functions, including the P-loop 
GXXXXGK(S/T) (residues 31-38), the guanine base binding loops NKXD (residues 145-
148) and EXSAK (residues 175-179) and the C-terminal farnesylation site CAXX 

















































Table 3.1.  Chicken Dexras1 cDNA and predicted amino acid sequences were compared 
with those of Human, Mouse, and Rat Dexras1 sequences. The comparisons were made 











































Figure 3.1.  (A) Predicted amino acid sequences for mouse, rat, human, and chicken 
Dexras1, were compared using the CLUSTALW command of Biology Workbench.  
Boxed groups of amino acids show motifs that are known to be essential for Ras 
functions.  (B) Phylogenetic tree representing Dexras1 amino acid sequence comparisons 





Tissue distribution of Dexras1 
     Previous studies have shown that Dexras1 is expressed in a variety of tissues in human 
and mice, including the brain, ovary, heart, kidney, skeletal muscle, pancreas, and 
liver133, 141.  Logically we wanted to determine which tissues expressed Dexras1 in the 
chicken.  Total RNA was isolated from spleen, pituitary, lung, brain, ovary, adrenal, 
kidney, and heart of juvenile chickens, and tissue distribution was determined by both 
Northern blotting and RT-PCR analysis.  In contrast to mouse and human tissues, both 
types of analysis showed that Dexras1 could only be detected in the pituitary in the 
chicken (Figure 3.2).  This finding, however, does not rule out the possibility that 
Dexras1 can become expressed at a later age in the chicken (i.e., sexual maturity), as the 




















































Figure 3.2. Tissue Distribution of Dexras1.  (A) 10 μg of RNA from adrenal, brain, heart,  
kidney, lung, ovary, pituitary, and spleen were subjected to Northern blotting for  
Dexras1.  Dexras1 mRNA is expressed  in high levels in the pituitary.  B) 1 μg of RNA  
from these tissues were subjected to RT-PCR using an anchored oligo-dT primer for the  
RT reaction and 1 set of Dexras1-specific internal primers for the PCR reaction.  
Genomic liver DNA (DNA) was used a negative control. Dexras1 cDNA was detected  




Developmental profile of Dexras1 expression during embryonic development 
     During the course of chicken embryonic development, plasma concentrations of 
glucocorticoids show two distinct patterns of increase.  The first occurs between e14 and 
e16 of embryonic development142, and the second occurs immediately before hatching 
(e20 through e21)143-145.  Knowing that the expression of Dexras1 is increased in response 
to glucocorticoids in mammals, we wanted to ascertain if the mRNA expression levels of 
Dexras1 fluctuated in conjunction with the plasma concentrations of glucocorticoids.  We 
isolated pituitaries from embryos on e11, e14, e17, and e20.  Next, we extracted the RNA 
and determined the levels of Dexras1 using qRT-PCR analysis.  We found that Dexras1 
showed two significant increases in its expression, the first occurring between e14 and 
e17, and the next occurring between e17 and 20 (Figure 3.3).  Thus the Dexras1 mRNA 
expression profile shown here is consistent with the reported plasma glucocorticoids 


















































Figure 3.3.  Developmental expression profile of Dexras1. On e11, e14, e17, and e20, 
pituitary glands were isolated and total RNA extracted mRNA was  reverse transcribed 
Using Dexras1 specific primers, qRT-PCR was performed to determine the amount of  
Dexras1 cDNA present.  Means without a common superscript differ (P<0.05). 
CORT  induction of Dexras1 in vivo 
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     To investigate the effect of CORT on the expression of Dexras1 in vivo, we injected 
1500 ng of CORT into the egg albumen of e12 embryos.  Two hours later, we isolated the 
pituitaries and extracted mRNA from CORT injected embryos as well as embryos 
injected with a control solution of 2.9% ethanol in deionized water.  The expression 
levels of chicken Dexras1 mRNA in the CORT treated and control treated e12 embryos 
were analyzed by quantitative real-time PCR (qRT-PCR) with Dexras1 specific primers.  
The results show that CORT was able to increase the amount of Dexras1 mRNA 
transcripts more than two-fold compared to the control injected group (Figure 3.4).  The 
findings show that CORT can increase pituitary Dexras1 mRNA expression quickly and 

































Figure 3.4.  Dexras1 is upregulated by CORT treatment in e12 chicken pituitaries.  Fertile 
e12 eggs were injected either with 1500 ng of corticosterone (black bar, n=3) or 2.9% 
ethanol (white bar, n=3) which served as a negative control.  2 hours later the pituitaries 
were isolated and RNA extracted.  Total RNA was reverse transcribed into cDNA using 
oligo-dT primers.  Using Dexras1 specific primers, qRT-PCR was performed to 








     In the present study we cloned and characterized the Dexras1 cDNA found in chicken.  
Our findings show that chicken Dexras1 is highly homologous at both the nucleic acid 
and protein levels to those of the Dexras1 forms found in human, mouse, and rat.  In 
contrast to other studies on the tissue distribution of Dexras1, our findings indicate that 
Dexras1 expression is limited to the pituitary gland (at least in 3-week old chickens).   
The expression profile of Dexras1 in the anterior pituitary gland during embryonic 
development appears to be positively correlated to circulating levels of CORT in the 
plasma of chickens.  Through in ovo injection of CORT we showed that Dexras1 is 
quickly and significantly induced in vivo.     
     Ras proteins have a very ubiquitous cell type distribution and are involved in a variety 
of cellular activities.  It is not surprising that Dexras1 has been proposed to have multiple 
diverse cell-specific functions.  Previous studies in our lab have shown that CORT can 
induce growth hormone gene expression in the chicken embryo both in vitro104 and in 
vivo108.  However, this effect of CORT requires the synthesis of one or more proteins120.  
We have also shown that the Ras inhibitor manumycin suppressed CORT stimulated 
increases in GH mRNA levels120.  These findings combined with our current results make 
it tempting to speculate that Dexras1 might be involved in glucocorticoid induction of 
GH gene expression.  However research needs to be done to define the exact role of 
Dexras1 in the chicken embryonic pituitary gland and to identify the anterior pituitary 
cell type(s) in the chicken pituitary that express Dexras1.   
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     The present study, as well as previous examinations, has shown that Dexras1 is 
quickly and strongly up-regulated in response to glucocorticoids.   This induction has 
been shown to occur in as little as 15 minutes133, 138, suggesting a direct action of 
glucocorticoids on Dexras1.  A functional glucocorticoid response element (GRE) has 
been found in the human Dexras1 gene in the 3’ flanking region (2.3 kb downstream of 
poly(A) signal)146.  This GRE conferred rapid glucocorticoid responsiveness when 
inserted into a homologous promoter-driven luciferase reporter, and a point mutation 
within the 15-bp GRE abolished this glucocorticoid responsiveness.  However, analysis 
of the 5’ and 3’ flanking region (5 kb of each region) and the 2 exons and 1 intron of the 
chicken Dexras1 gene using the vertebrate TRANSFAC transcription factor matrix within 
TESS (http://www.cbil.upenn.edu/cig-bin/tess/tess33/) yielded only multiple potential 
GRE half-sites.  In spite of this observation, it has been shown that glucocorticoids can 
regulate the expression of various genes through trans-activation mechanisms147, 148. 
     In summary, chicken Dexras1 is highly similar in nucleic acid and amino acid 
sequence to those of the human, mouse, and rat forms.  As seen with in vitro and in vivo 
models from other species, chicken Dexras1 is positively regulated by exposure to 
glucocorticoids.  Its tissue distribution restriction to the pituitary gland and lack of any 
potential GRE sequences within 1 kb of the gene (both 5’ and 3’) might imply a 
distinctive mechanism of glucocorticoid action on chicken Dexras1 gene expression.  Its 
ontogeny of expression during embryonic development of the chick anterior pituitary 
gland suggests that Dexras1 might function in glucocorticoid regulation of pituitary 
differentiation or gene expression, including negative feedback on POMC expression or 
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induction of GH expression.  Future research is needed targeting the functional role of 

































CHAPTER 4:  Characterization of Glucocorticoid-Induced Changes in Gene Expression 
in the Embryonic Pituitary Gland 
INTRODUCTION 
     The embryo of the domestic chicken (Gallus domesticus) provides a fitting vertebrate 
model to study pituitary cell differentiation in that 1) it can easily be manipulated without 
confounding maternal interferences and 2) the pattern of anterior pituitary cell 
differentiation is similar to that of mammals149.  The pituitary gland is a highly 
vascularized structure that is composed of two parts from two different embryonic germ 
layers.  The posterior portion of the gland is derived from neural origin, while the anterior 
portion, called the adenohypophysis, originates from oral ectoderm.  The fully 
differentiated anterior lobe of the gland is composed of the following five different cell 
phenotypes: 1) Lactotrophs, which secrete prolactin (PRL); 2) Thyrotrophs, which secrete 
thyroid stimulating hormone (TSH); 3) Gonadotrophs, which secrete luteinizing hormone 
(LH) and follicle stimulating hormone (FSH); 4) Corticotrophs, which secrete 
adrenocorticotropic hormone (ACTH); and 5) Somatotrophs, which secrete growth 
hormone (GH). 
     We have previously established that between embryonic day (e) 13 and e16 of chicken 
embryonic development, a considerable rise in the number of somatotrophs takes place, 
even though an occasional somatotroph can be detected earlier97, 99.  Somatotrophs lack 
the ability to differentiate spontaneously and require a blood-borne extrapituitary signal 
for their induction in culture103.  We demonstrated that serum from e16 embryos but not 
that from e12 embryos was able to stimulate somatotroph differentiation in cultures of 
e12 pituitary cells, which is four days in advance to the time that somatotroph 
differentiation would typically occur in the chick embryo103. This factor contained in the 
57 
 
serum of e16 embryos was ether-soluble, bound by a trypsin-sensitive protein, and was 
heat-stable104.  These characteristics suggested that this blood-borne factor was a steroid.  
Consequently, we showed that the blood-borne signal capable of prematurely inducing 
somatotroph differentiation was the adrenocortical glucocorticoid CORT104. 
     The ability of glucocorticoids to stimulate somatotroph differentiation during 
embryonic development is not restricted to chickens.  Oral administration of a synthetic 
glucocorticoid, dexamethasone (Dex), to pregnant rats induces early GH expression in 
the corresponding day 17 or day 18 fetuses150, 151.  It has also been reported  that 
glucocorticoids can  effectively stimulate GH cell differentiation in pituitary cultures 
derived from rats112, 150, 152. 
     When e11 chicken embryos were treated in vivo with CORT, the number of cells that 
secreted GH was augmented on e13, and this reaction involved elevated expression of 
GH mRNA in the caudal portion of the anterior pituitary gland108, 117.   In cultures of e12 
pituitary cells, CORT was able to increase GH mRNA due to an increase in the amount 
of cells expressing GH mRNA110, 120.   In addition, treatment with the protein synthesis 
inhibitor cycloheximide (CHX) completely blocked CORT induction of GH mRNA, 
indicating that the response requires the ongoing synthesis of one or more proteins.   
Furthermore, treatment with CORT failed to induce somatotrophs prior to e11, and 
premature somatotroph induction by CORT does not does not alter the quantity of GH 
cells later in development117.  Taken together, these results indicate that corticosteroids 
are involved in the terminal steps of somatotroph differentiation in the chicken embryo, 
that the corticosteroid-induced increase in GH gene expression and GH secretion is 
limited to a group of cells that are already committed to become somatotrophs, and that 
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glucocorticoid induction of GH gene expression is indirect, involving synthesis of 
another protein(s). 
     Our hypothesis is that this unknown “intermediate” protein(s) synthesized in response 
to CORT ultimately induces GH gene expression and somatotroph differentiation.  The 
purpose of this study was to identify this unknown protein(s) that is involved in CORT 
induction of GH mRNA during chicken embryonic development. To help in identifying 
potential candidate genes for this intermediate protein(s), we used a high-density chicken 
cDNA microarray.  The DEL-MAR 14K Integrated Systems Microarray contains 14,053 
cDNAs assembled from the neuroendocrine system, the reproductive system, the liver, 
adipose tissue, and skeletal muscle.  Based on this microarray analysis, candidate genes 
were identified, and the effects of overexpression of these genes in transient transfection 
assays were determined. 
 
MATERIALS AND METHODS 
Animals and pituitary dispersions 
     All animals were Ross broiler strain chicken embryos purchased from Allen’s 
Hatchery (Seaford, DE). All procedures were approved by the Institutional Animal Care 
and Use Committee. All hormones and other chemicals were purchased from Sigma (St. 
Louis, MO) unless otherwise stated. Embryonic day 0 (e0) was defined as the day when 
the eggs were placed in a humidified incubator (G.Q.F. Manufacturing, Savannah, GA) at 
37.5 °C. The typical incubation length for chickens is 21 days. On e11, the embryos were 
removed and their pituitary glands isolated using a dissecting microscope. The pituitaries 
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     Dispersed pituitary cells were plated (~1 X 106 cells/well) in poly-L-lysine coated 12-
well culture plates in serum-free medium (D-MEM/F-12 nutrient mixture; Invitrogen, 
Carlsbad, CA) supplemented with 0.1% bovine serum albumen (BSA), 5 μg/ml bovine 
insulin, 5 μg/ml human transferrin, 100 U/ml penicillin G, and 100 μg/ml streptomycin 
sulfate. Cells were allowed to attach for 1 h in a 37.5 °C, 5% CO2 atmosphere (VWR 
Model 2250; VWR International, West Chester, PA). Cells were then either 1) pretreated 
for 1.5 h with 10 μg/ml CHX and then subsequently cultured in the presence of CORT 
(10-9M) for 0, 1.5, 3, 6, 12, or 24 hrs, or (2) cultured with corticosterone (10-9M) with no 
CHX pretreatment for 0, 1.5, 3, 6, 12, or 24 hrs.  The concentration of CHX (10 μg/ml) 
was chosen because it was previously shown to block GH mRNA up regulation120.  
CORT stock solution (10-3M) was prepared in absolute ethanol and further diluted in cell 
culture medium.  Wells were randomly selected for each treatment/time point.  Untreated 
cells served as a control. All cells were maintained in culture for 24 h regardless of 
treatment. At the end of the 24 h culture period, cells were retrypsinized and immediately 






RNA Isolation, Amplification, and In Vitro Transcription 
     Total RNA was isolated from the cultured pituitary cells using a RNeasy Mini Kit 
(QIAGEN Inc., Valencia, CA) according to the manufacturer’s protocol, and quantified 
using the RiboGreen RNA Quantitation Kit (Invitrogen).  To remove any contaminating 
DNA, each sample was treated with DNAse I.  The pituitary gland of a chicken embryo 
does not provide ample RNA for microarray analysis.  For that reason we utilized an 
earlier detailed153 variation of the Eberwine procedure154 to amplify mRNA. Briefly, 0.5 
μg of total RNA was reverse-transcribed with SuperScript II (Invitrogen, Carlsbad, CA) 
and an oligo(dT) primer containing a T7 promoter site (5’-
GGCCAGTGAATTGTAATACGACTCACTATAGGGAGGCGGT24-3’, Affymetrix, 
Santa Clara, CA). After second strand synthesis, phenol-chloroform was used to extract 
the double-stranded cDNA; afterwards the cDNA was filtered with a Microcon-30 
column (Millipore, Billerica, MA).  Lastly, the double-stranded cDNA was used as a 
template for in vitro transcription with the T7 MEGAscript kit (Ambion, Austin, TX) 
according to the manufacturer’s protocol. The amplified RNA (aRNA) that resulted was 
phenol-chloroform extracted, purified with a Spin Column-30 (Sigma, St. Louis, MO), 
and then the quantity was measured using the RiboGreen RNA Quantitation Kit 
(Invitrogen).  This amplification procedure was validated in a previous microarray study 







Production of the Del-Mar 14K Integrated Systems Microarray 
     The cDNA library used to make the microarrays was generated from RNA isolated 
from the neuroendocrine system (hypothalamus, anterior pituitary gland, and pineal 
gland), reproductive system (ovary, testes, and oviduct), and metabolic/somatic systems 
(liver, skeletal muscle, epiphyseal growth plate, abdominal fat) of chickens ranging in 
age from e12 to d63 and has been described previously140, 153. The construction and 
normalization of our chicken cDNA  library was performed as a custom service by a 
commercial company (Life Technologies Inc., Rockville, MD; now Invitrogen) and has 
been described in detail elsewhere156.  The DNA sequencing of the unigene clones was 
carried out at Dupont’s high-throughput sequencing facility (Agricultural Products 
Division E.I. du Pont de Nemours & Co, Inc., Delaware Technology Park, Newark, DE) 
according to their protocols.  The clone annotation process is described in detail by Carre 
and collegues156.   
     The unigene clones were cultivated overnight in Terrific Broth (Sigma) in 96-well 
PCR plates.  They were then lysed, and the inserts were PCR amplified from the 
pCMV·Sport6.1 vector (Invitrogen) using SP6 (5’- 
GGCCTATTTAGGTGACACTATAG-3’) and T7 (5’- 
GCTTATAATACGACTCACTATAGGG-3’) vector-specific primers (Sigma Genosys, 
The Woodlands, TX). The PCR products were detected by staining with ethidium 
bromide in 1% agarose gels.  An annotated registry of the clones and their spot on the 
DEL-MAR 14K Integrated Systems microarrays can be found at the Gene Expression 
Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/) data repository (Platform Accession 
# GLP1731; National Center for Biotechnology Information (NCBI), Rockville, MD). 
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The GEO file also provides links to the cDNA sequence, contig sequence, BLASTN and 
BLASTX alignments, and chromosomal location. 
 
Microarray hybridization and data analysis 
     Samples were hybridized to the microarrays using a reference design157.  An internal 
reference sample was generated by labeling an aliquot of an RNA pool made from all the 
RNA samples with Cy5.  The RNA from the experimental samples were tagged with Cy3 
and hybridized to an array with an aliquot of the Cy5 labeled pool from each study. This 
design resulted in the use of 48 microarrays (12 treatment groups per replicate, n=4) for 
the 24 hr global analysis study. 
     The labeling of the cDNA with both Cy3 and Cy5, microarray hybridization, and 
image scanning were carried out at the University of Maryland Biotechnology Institute’s 
Microarray Core Facility (http://www.umbi.umd.edu/~cbr/macore/macorestart.htm, 
Rockville, MD). Generation of the Cy3- or Cy5-labeled target cDNA was done in a two-
step process.  First, 1 μg aRNA was reversed transcribed using random primers with the 
Amino Allyl cDNA Labeling Kit (Ambion).  Next, both Cy3 and Cy5 mono-reactive 
esters were attached to the cDNA (Amersham Biosciences, Piscataway, NJ).  The labeled 
cDNA targets were then filtered from the unincorporated fluorescent dyes with the 
CyScribe GFX Purification Kit (Amersham).  Microarray hybridization was carried out 
overnight at 42 °C with the Cy3-labeled experimental samples and an aliquot of the Cy5-
labeled reference pool using microarray hybridization buffer (Amersham).  After the 
overnight hybridization, the slides were washed with increasing salt sodium citrate 
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stringency and then scanned with a 418 confocal laser scanner (Affymetrix) at 550 nm for 
Cy3 and 649 nm for Cy5, generating two TIFF images for each slide. 
     The data obtained from the microarray analysis was processed and normalized using 
software that is part of the TM4 suite of microarray data analysis applications158 offered 
by The Institute for Genomic Research (TIGR, Rockville, MD). Two TIFF images for 
each slide were processed using Spotfinder (version 2.2.4).  Afterwards, the data that 
were determined with Spotfinder were exported to the Microarray Data Analysis System 
(MIDAS; version 2.18) to be normalized. Lowess normalization was carried out on the 
data from the Cy3 channel without background correction.  Next, the data underwent 
standard deviation regularization first by block then by slide, with Cy5 (the pooled RNA 
sample) as the reference.  The fluorescent intensity of each spot was calculated by 
dividing the total fluorescene (pixels) by the spot area.  The background fluorescence was 
determined for each slide by taking the mean Cy3 and Cy5 fluorescence values of the 8 
control spots (salmon testes DNA) on each slide.  Any spot whose Cy3 or Cy5 
fluorescence intensity levels were below background was deleted from further analysis.       
Spots whose fluorescence intensity levels (both Cy3 and Cy5) was above background 
were corrected by subtracting the average Cy3 and Cy5 background fluorescence of each 
slide from the corresponding Cy3 and Cy5 fluorescence intensity values for each spot.  
Data were then analyzed as log2(corrected Cy3/corrected Cy5), or log2-ratio, for each 






Plasmid constructs and transfection experiments 
     Plasmids containing the full length cDNAs for Dexras1, Prostaglandin-D Synthase, 
and RASDVA were obtained from the clones produced in our cDNA library (see above).  
Briefly, these clones were grown overnight in Terrific Broth (Sigma), and the plasmids 
were prepared for the transfection studies using a Nucleobond Maxiprep Plasmid 
Isolation Kit (Clontech, Palo Alto, CA).  Plasmids were sequenced in both directions by 
the University of Maryland DNA Sequencing Facility using AmpliTaq-FS DNA 
polymerase and Big Dye terminators with dITP (Perkin-Elmer/Applied Biosystems; 
Foster City, CA) and an Applied Biosystems DNA sequencer (model 3730) and the 
integrity of the plasmids was confirmed by gel electrophoresis.  Dispersed e11 pituitary 
cells (~3 X 106 cells/treatment group) were cultured in serum-free Opti-MEM® I 
Reduced Serum Media (Invitrogen) and then were transfected with either an empty 
pCMV-Sport6.1 vector, Dexras1 (clone: pgp1n.pk012.a14, Accession# BX930456)  
Prostaglandin-D Synthase (clone: pgl1n.pk007.j7, Accession# CAA07005), or RASDVA 
(clone: pgp2n.pk003.j19, Accession# AY729886)  plasmid along with a Golgi-targeted 
Green fluorescent protein (GFP)-expression vector159, which served as a transfection 
control.  The cells were transfected using the LipofectamineTM 2000 Transfection 
Reagent (Invitrogen) according the manufacturer’s instructions for a 6-well culture plate.  
The cells were transfected in suspension for 2 hrs at 37 °C, then plated into duplicate 
wells of a 6-well culture plate and placed back into the incubator for another 4 hrs.  At 
the end of the 4 hr incubation, the Opti-MEM® I Reduced Serum Media was removed 
and the cells were re-cultured in serum free DMEM-F12 for 24 hrs at 37 °C.  After 24 
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hrs, one well from each transfection group was treated with CORT (10-9 M) for 18 hrs 
while the other well of the same transfected group was left untreated.   
     After the 18 hr incubation period, the cells were retrypsinized as described above and 
sorted into GFP+ and GFP- cell groups by fluorescence-activated cell sorting (FACS) at 
the laboratory of Dr. H. Dave Guthrie of the United States Department of Agriculture 
(Biotechnology and Germplasm Division, Beltsville, MD) according their protocols.   
Samples were analyzed on a MoFlo High Speed Flow Cytometer (Dako-Cytomation Inc., 
Fort Collins, CO) equipped with a 200 mW air-cooled 488 nm Coherent Innova 300 
laser.  Green GFP fluorescence was collected after a 530/30-nm bandpass filter.  Cells 
were sorted under a flow rate of 500-800 cells/sec in a sheath of PBS under 40 psi.  On 
each sample, a minimum of 30,000 GFP+ cells were collected.  The MoFlo cytometer 
utilized Summit software from Dako-Cytomation to collect and analyze data. GFP+ and 
GFP- cells were immediately frozen in liquid nitrogen and stored at -80 C until RNA 
extraction.  RNA was extracted and quantified as described above, and 20 ng of total 
RNA was used for the reverse transcription reaction that was carried out with the 
oligo(dT) primer containing a T7 promoter.  This experiment was repeated 4 times. 
 
Primer Design 
     Primers (Sigma Genosys) used for PCR were designed using the PRIMER3 design 
tool within Biology Workbench maintained by the San Diego Super Computer Center 
(http://workbench.sdsc.edu/), and were designed from the contig or singlet sequence for 
that cDNA.  All cDNA sequences are available from an online searchable database 
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(http://cogburn.dbi.udel.edu/).  The sequences off all the primers that were used are listed 
in Table 4.1. 
 
 
Gene Forward (5' - 3') Reverse (5' - 3') 
CCO GCATGGAGTGGAAATACGGT GCACATCCGAGAGACACAAG 
SMARCD1 ACTCAGACTCGCCCAGTGAT TCCGCTGGGATTCAAATATC 
LSM7 GATGGCGGATAAGGAGAAGA ACCACTTGCTTCTCTCCCAC 
PLEKHB1 CTCTGGAGGCAGAGTTCCAT GCACGAACCAATTCCTCTTC 
CEPU AGAAGGGCATCCTGATGTGT CAGCCCTTTCTGTCCTTCAG 
FBP CAGGGACAGGTCATTTCACA CAGCTGGATCGTACCTAGCC 
PMPP22a TCTCCTTCCTGGCCTTTGTA TCATTCATTGCCCTCCTCTT  
SUMO2 CCACAACCTTGGGAGAAGAG GCCAGTGGAACCCTATCAAA 
SEMA7A CAAATTCCCTCGTCATCGTT AGAGCTCTCCATCCCCTTTC 
NOTCH GAGCCAGTTGGAGAAGATGC CTGCCATGTTACCCTCTGGT 
Dexras1 GGTCTACCAGCTCGACATCC TGAACACGAGGATGAAAACG 
PDS2 ACGCTCCTGTCCTACAAAGC CTCTGTCCCTGAGAGCCAAC 
Ras-dva AGGAAGCTCTCCATCCAGAA GGAGGGAATTTGTCCTCCTT 
Beta-actin TTCTTTTGGCGCTTGACTCA GCGTTCGCTCCAACATGTT 
POMC AGGGACCTCAGGGATCATCAA TGTTCAAGGGCAGGTTGGA 
PRL ACCTGTGGGCTGCATTACTCA AAGTTACTGATGATCCTGGTGCTGTA 
GH TTCAAGAAGGATCTGCACAAGGT CTCAGATGGTGCAGTTGCTCTCT 
IAP3 GAGCACAAGAGGCATTTTCC ATTCTGCCATGGATGGATTC 
Selenoprotein I TTCCTGCTGCTTGTCTTCAA GAGCTTGTTTGCCATCAACA 











     Two-step qRT-PCR was used to validate gene expression patterns from the microarray 
analysis and levels of gene expression from the overexpression studies.  Reverse 
transcription reactions were carried out using SuperScript III (Invitrogen) with random 
primers (Invitrogen) for aRNA or the oligo-dT primer containing a T7 promoter site 
primer for T-RNA used in the transfection studies.  Reverse transcription reactions (20 
μl) were done using 500 ng aRNA for the microarray verification analysis or 20 ng T-
RNA for the overexpression analysis.  As a negative control for genomic DNA 
contamination, a pool of all the RNA from a given experiment was made, and the 
reaction conducted as the others except reverse transcriptase was not added. All reactions 
were diluted to 40 μl (2-fold) prior to PCR analysis. The diluted RT samples (2 μl) were 
then analyzed using the SYBR Green PCR Master Mix (Applied Biosystems) and a Bio-
Rad iCycler. 
     Each PCR reaction (12 μl) contained 1 μl of diluted cDNA, 5 μM of each primer, and 
6 μl of 2X PCR buffer (described below). Cycling parameters were: initial denaturation at 
95 °C for 5 min, followed by 40 cycles of 95 °C for 15 sec and 55 °C for 45 sec. 
Dissociation curve analysis and gel electrophoresis were conducted to ensure that a single 
PCR product of appropriate size was amplified in each reaction. The data were 
transformed using the equation 2-Ct, where Ct is the threshold cycle, the fractional cycle 
number when the amount of amplified product reaches a fixed threshold for fluorescence 
due to binding of SYBR green to the double-stranded PCR product. For the microarray 
verification experiments, the data were divided by the mean of the highest level of gene 
expression for each technique for statistical analysis and comparison with the microarray 
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results.  For the transfection experiments, the data were divided by the mean of the 2-Ct 
value of the control group in a given experiment. 
 
Statistical Analysis 
     Statistical analyses were performed using Statistical Analysis System (SAS) version 
8.02 (SAS Institute, Cary, NC). Microarray data (Log2 ratios) were subjected to one-way 
analysis of variance (ANOVA) to identify spots that were differentially expressed on at 
least one of the time points.  Differences were considered significant at P≤0.05.  Levels 
of mRNA reported are the means and standard errors of the relative expression levels 
described above. Prior to statistical analysis, qRT-PCR data were transformed to correct 
for heterogeneity of variance among treatment groups by taking the log10 of the relative 
expression levels. Results were then analyzed by analysis of variance using the PROC 
MIXED procedure of the Statistical Analysis System (SAS; SAS Institute; Cary, NC). 
Differences between treatments were compared using the PDIFF procedure (SAS). 












Time course of CORT induction of GH mRNA 
     In order to ascertain which genes could be involved in CORT induction of GH mRNA 
during chicken embryonic development, the time course of CORT induction of GH 
mRNA was studied.  To date the earliest time point at which CORT has been shown to 
stimulate GH mRNA in chicken embryos is 4 hrs160.  Thus our first goal was to assess the 
expression of GH mRNA as a marker to identify genes regulated earlier by CORT.  As 
shown in Figure 4.1, GH levels continued to significantly increase until 3 hrs after CORT 
treatment, where they no longer increased significantly, but GH mRNA levels remained 
elevated compared to the 0 hr time point throughout the 24 hr culture period.  
Interestingly, GH mRNA levels were induced more than 2 fold within 90 minutes of 
CORT treatment.  In addition, CORT induction of GH mRNA was blocked by 
pretreatment with the protein synthesis inhibitor cycloheximide (CHX), as previously 
reported120.  As a result of the data shown in Figure 4.1, we defined early CORT 
regulated genes as those whose expression was affected (induced or repressed) at least 2-
fold within 3 hr after CORT treatment.  Those genes whose expression levels were 
regulated at least 2-fold after 3 hrs (6, 12, and 24 hr) of CORT treatment were considered 





















e course of GH mRNA after CORT administration.  Dispersed e11 
ituitary cells were either pretreated for 1.5 h with 10 μg/ml Cycloheximide (CHX) and 
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retreatment group.  Values denoted with an asterisk (*) were significantly different from 
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Microarray analysis after 24 h of CORT treatment 
   Because the goal of the microarray study was to identify candidate primary response 
enes that may mediate CORT induction of GH mRNA, we chose the 3 hr time point as 
e early time point marker and the time points 6, 12, and 24 hr as late markers.  The 
y3-labeled aRNA that was prepared from RNA isolated from dispersed e11 pituitary 




se to display the distribution of 
ose genes at each time point that were either initially upregulated or down regulated 











hybridized to our DEL-MAR 14K Integrated Systems microarray chips with Cy5-lab
aRNA from a pool of all experimental samples.  Table 4.2 displays the output from the 
microarray analysis with the background corrected log2 Cy3/Cy5 ratios and p values fo
those spots on the array that showed a significant difference between any two time p
a total of 388 genes (p < 0.05). 
     From the 388 significant genes from table 4.2, we cho
th
compared to the control time point 0 hr.   As seen in
that were at least 2-fold upregulated at 1.5 hr, that was nearly twice as much as those that
were downregulated at the same time point (28 genes).  At the 3 hr time point, there 
appeared to be an inverse of the proportion of transcripts that were up/down-regulated
compared to the 90 min time point, with only 3 transcripts showing a significant increase 
in expression levels and 24 showing a reduction.   At the later time points (6, 12, 
hr), the number of transcripts that were significantly induced or repressed gradually 
decrease, culminating at the 24 hr time point were only 4 genes showed an increase in 
expression levels and only 1 transcript was significantly repressed.     We then decided to
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on the initial effect of CORT treatment on their levels of expression.  This categorization 




CORT.  The 5 categories that we chose were: (1) Genes that were induced early (i.e., at 
least 2-fold within 3 hr), (2) Genes that were repressed early, (3) Genes that were induced 
late (i.e., at least 2-fold between 6 – 24 hr), (4) Genes that were repressed late, and (5) 
Genes that displayed no significant effect at any time point compared to basal (time point 
0 hr).  The microarray analysis detected a total of 49 transcripts that were significantl
increased early (i.e., within 3 hr), 48 that were significantly decreased early, 20 and 13 
that were significantly increased and decreased late, respectively, after CORT treatment 
(Table 4.3).  The distribution of transcripts being either induced or repressed during the 
24 hr culture period from figure 4.2 and table 4.3 implies a trend that CORT regulate
expression of genes (either directly or indirectly) during shorter time intervals than at 
later time points.  This finding is not all that surprising given the fact that the lipophilic 
nature of glucocorticoids (and other steroids) allows them to freely diffuse in and out of 
the cell, which would allow their effects on gene expression to more immediate.  It has 
been shown previously that glucocorticoids can affect gene expression in a matter of
seconds/minutes161, 162.   
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Spot ID 0_B 1.5_B 3_B 6_B 12_B 24_B p_B 0_CHX 1.5_CHX 3_CHX 6_CHX 12_CHX 24_CHX p_CHX
1 1.1.1 -4.04 -0.29 -1.24 -2.27 -2.38 -3.33 0.00 -2.26 0.20 0.47 2.37 0.74 0.95 0.0
105 2.2.5 -0.50 0.33 -0.13 -1.11 0.08 -0.90 0.04 -0.52 0.77 -0.27 0.88 0.71 -0.07 0.28
302 4.4.2 -0.25 -0.04 -0.13 -0.28 0.13 -0.23 0.05 -0.14 0.00 -0.10 -0.11 0.23 -0.15 0.20
309 4.4.9 -0.44 0.45 -0.64 2.01 2.53 0.00 0.27 2.77 2.39 0.51
368 3.5.8 -0.26 -0.81 0.05 -0.12 -0.16 -0.16 0.03 -0.22 0.07 0.29 -0.21 -0.50 0.14 0.
461 4.6.1 -0.10 0.11 -0.09 -0.20 -0.11 -0.39 0.04 0.06 0.12 0.05 0.13 0.34 0.03
481 1.7.1 -0.46 -0.25 -0.16 0.04 0.29 -0.04 0.02 -0.48 -0.31 -0.40 -0.21 0.15 -0.28 0.0
533 3.7.13 -0.26 0.08 -0.07 -0.13 0.09 -0.11 0.02 0.01 0.01 -0.03 -0.01 0.14 0.05 0.6
541 4.7.1 -0.29 0.32 -0.42 -1.35 1.03 -0.08 0.02 0.09 0.30 -0.09 0.68 0.69 -0.29 0.2
570 1.8.10 0.02 -0.71 0.12 0.05 0.25 -0.15 0.00 -0.18 -0.14 0.17 -0.48 -0.66 0.13 0.03
598 2.8.18 -0.09 -0.77 0.05 -0.07 -0.19 -0.03 0.01 -0.08 -0.12 0.25 -0.25 -0.66 0.30 0.00
652 1.9.12 0.07 -0.47 0.22 0.15 0.02 0.19 0.04 0.10 0.09 0.42 -0.16 -0.66 0.34 0.0
758 2.10.18 0.02 -0.51 0.01 0.07 -0.09 0.06 0.02 -0.16 -0.26 0.06 -0.19 -0.48 -0.03 0.1
848 3.11.8 0.02 -0.37 0.11 0.05 -0.07 -0.13 0.04 -0.06 -0.03 0.11 -0.40 -0.35 0.11
1043 1.14.3 0.68 0.87 -0.21 0.20 -0.11 -0.07 0.02 0.51 0.51 -0.57 0.91 -0.15 -2.08
1138 1.15.18 -0.12 -0.35 -0
1215 1.16.15 0.06 -0.37 0.
1







614 3.8.14 0.00 -0.46 0.07 0.02 -0.22 -0.04 0.02 -0.08 -0.28 -0.06 -0.47 -0.57 -0.08 0.01
3
8
790 4.10.10 -0.06 -0.26 -0.03 -0.01 0.23 0.15 0.04 -0.02 0.07 0.04 0.00 0.12 -0.04 0.92
0.05
0.00
1078 2.14.18 -0.38 -0.03 -0.29 -0.34 0.73 0.01 0.00 -0.12 1.31 -0.02 0.72 0.70 0.03 0.45
.05 0.05 -0.02 0.23 0.01 -0.17 -0.13 0.24 0.38 -0.11 0.10 0.00
23 0.18 -0.01 0.16 0.02 0.10 0.11 0.35 0.04 -0.20 0.32 0.20
1232 2.16.12 -0.02 -0.52 0.28 0.09 -0.03 0.13 0.03 0.10 -0.08 0.38 -0.04 -0.34 0.27 0.19
1255 3.16.15 -0.18 -0.77 0.18 0.09 -0.13 0.00 0.04 -0.04 0.00 0.31 -0.35 -0.40 0.12 0.22
1260 3.16.20 0.01 -0.35 0.06 0.06 -0.11 0.07 0.02 -0.06 -0.03 0.18 0.05 -0.31 -0.03 0.11
1405 3.18.5 -0.10 -0.23 0.08 0.05 -0.33 -0.11 0.02 -0.01 -0.12 0.22 -0.01 0.14 0.31 0.15
1637 6.1.17 -0.31 0.05 -0.23 -0.49 -0.15 -0.28 0.02 -0.07 0.14 0.10 0.36 0.28 0.19 0.83
1765 5.3.5 0.03 0.54 -0.55 0.65 0.77 3.31 0.03 0.01 -0.44 -1.62 -0.31 -1.04 -2.06 0.15
1808 7.3.8 0.22 0.15 0.21 -0.06 -0.45 -0.26 0.00 0.15 0.03 0.08 0.19 -0.26 -0.06 0.14
1818 7.3.18 0.49 0.97 -0.42 0.42 1.10 1.62 0.03 0.58 -0.03 -1.74 -0.97 -0.93 -0.38 0.31
1876 6.4.16 0.76 0.73 -0.11 -0.93 3.50 0.05 -0.09 0.41 0.15 2.17 -0.33 3.35 0.26
1951 6.5.11 0.06 0.44 0.03 -0.17 0.20 -0.08 0.00 0.14 0.10 0.00 0.21 0.36 0.00 0.09
1985 8.5.5 -0.02 0.09 -0.15 -0.12 0.35 -0.29 0.01 0.10 0.17 0.04 -0.07 0.33 -0.34 0.17
2081 5.7.1 -0.51 -0.35 -0.44 -0.60 -0.21 -0.29 0.04 -0.40 -0.11 -0.26 -0.24 0.04 -0.09 0.01
2172 5.8.12 0.05 -0.26 0.08 0.04 -0.02 -0.04 0.01 0.07 0.10 0.15 0.07 -0.21 0.18 0.01
2174 5.8.14 -0.88 -0.42 -0.25 0.61 -0.14 0.07 0.01 -1.52 -0.79 -0.15 0.66 0.60 0.65 0.00
2248 5.9.8 -0.06 0.03 0.14 0.09 -0.12 -0.14 0.02 -0.02 0.04 0.07 0.06 -0.05 0.09 0.52
2276 6.9.16 0.26 -0.38 0.37 0.36 -0.08 0.25 0.03 0.26 0.18 0.30 0.10 -0.48 0.30 0.03
2338 5.10.18 0.14 -0.46 0.09 0.06 -0.05 0.06 0.02 -0.14 -0.14 0.07 -0.15 -0.46 0.05 0.04
2446 7.11.6 -0.46 0.03 -0.29 -1.25 -0.09 -0.50 0.02 -0.23 -0.49 -0.17 -0.72 0.17 -0.42 0.29
2644 5.14.4 -3.05 0.35 -0.10 0.42 0.30 0.48 0.00 0.08 0.39 0.13 0.56 0.48 0.00 0.68
2647 5.14.7 -0.04 -0.52 -0.09 -0.09 -0.10 -0.10 0.05 -0.27 -0.15 0.18 -0.11 -0.45 0.08 0.00
2650 5.14.10 -0.15 -0.55 -0.04 -0.07 -0.19 -0.05 0.03 -0.13 -0.07 0.16 -0.06 -0.44 0.19 0.01
2671 6.14.11 -0.08 -0.71 -0.06 0.01 -0.14 0.03 0.05 -0.04 -0.18 0.19 -0.27 -0.52 0.06 0.06
2694 7.14.14 -0.14 0.03 0.11 -0.03 0.28 0.10 0.01 -0.02 0.08 0.06 -0.06 0.34 0.04 0.33
2756 6.15.16 -0.13 -0.83 -0.12 -0.18 -0.22 -0.07 0.05 -0.17 -0.25 0.10 -0.29 -0.53 0.08 0.13
2758 6.15.18 -0.19 -0.74 -0.33 -0.17 -0.31 -0.19 0.05 -0.18 -0.17 0.07 -0.13 -0.36 0.11 0.30
2811 5.16.11 -0.06 0.16 0.03 -0.29 0.21 -0.11 0.01 -0.01 -0.04 -0.02 0.33 0.36 -0.07 0.18
2815 5.16.15 -0.01 0.18 0.07 -0.32 0.37 1.76 0.02 0.40 0.76 0.44 0.77 0.85 0.10 0.92





Table 4.2.  The output from the microarray analysis.  The table shows the spot number of 
the clone (Spot), the position on the array that each clone occupied (ID), and the 
background corrected log2 Cy3/Cy5 ratios for each spot for the 0, 1.5, 3, 6, 12, and 24 hr 
time points under basal (B, with CORT alone) and cycloheximide pretreated (CHX) 






Spot ID 0_B 1.5_B 3_B 6_B 12_B 24_B p_B 0_CHX 1.5_CHX 3_CHX 6_CHX 12_CHX 24_CHX p_CHX
2862 8.16.2 -0.84 -0.14 -0.04 -0.05 -0.33 -0.11 0.01 -1.02 -0.21 0.02 1.05 0.46 0.01 0.01
2898 5.17.18 1.31 0.66 1.36 2.71 -0.24 7.26 0.00 1.14 0.47 0.94 1.66 10.11 -0.02 0.09
2953 8.17.13 0.08 0.04 0.49 -0.60 2.61 1.82 0.00 0.05 0.22 -4.10 0.59 -1.04 0.07
3205 9.1.5 -0.01 -0.42 -0.06 -0.12 -0.14 -0.13 0.03 -0.28 -0.09 0.02 -0.22 -0.33 0.01 0.03
3225 10.1.5 -0.30 0.03 0.14 -1.11 1.10 3.82 0.01 0.39 0.85 1.25 0.24 0.70 0.62 0.99
3296 9.2.16 0.04 0.34 -0.01 -0.13 -0.11 -0.14 0.03 0.19 0.15 0.21 0.04 0.09 0.22 0.90
3320 10.2.20 0.17 0.15 0.07 0.04 -0.42 -0.35 0.01 -0.08 0.13 0.16 0.12 -0.15 -0.06 0.24
3338 11.2.18 0.24 0.18 -0.38 0.06 -0.60 2.07 0.01 0.14 0.96 -0.22 -0.21 -1.04 0.74
3404 11.3.4 -0.31 0.19 -0.23 -0.32 1.23 0.22 0.01 -0.36 -0.12 -0.10 0.51 1.38 0.09 0.10
3408 11.3.8 -1.31 2.57 1.62 1.16 1.18 2.49 0.01 -0.37 1.54 -0.69 -1.62 -3.07 -2.63 0.12
3492 11.4.12 0.20 -0.18 0.07 0.13 -0.03 0.29 0.04 0.02 -0.07 0.06 -0.38 -0.78 -0.15 0.04
3528 9.5.8 0.01 0.12 0.04 0.02 -0.09 -0.18 0.01 0.07 0.03 0.05 0.13 0.09 0.00 0.76
3572 11.5.12 -0.27 0.63 -0.15 -0.23 0.22 -0.21 0.00 0.08 0.04 -0.04 0.16 0.45 -0.13 0.31
3581 12.5.1 0.24 0.63 0.22 0.33 2.97 7.31 0.01 0.74 0.10 -0.26 0.08 1.54 1.10 0.46
3623 10.6.3 0.18 0.70 0.07 -0.20 0.02 -0.16 0.04 0.18 0.28 0.02 0.37 0.53 -0.26 0.06
3643 11.6.3 -0.27 0.53 -0.04 -0.10 -0.07 0.03 0.03 0.25 0.01 -0.09 0.03 -0.03 -0.02 0.74
3644 11.6.4 -0.48 0.60 -2.17 0.28 1.03 1.36 0.03 0.52 0.60 0.06 1.82 3.14 0.13 0.14
3839 12.8.19 -0.06 -0.27 0.19 0.07 -0.10 -0.02 0.04 -0.17 -0.11 0.15 -0.07 -0.64 -0.12 0.03
3858 9.9.18 0.05 -0.29 0.09 0.05 -0.02 0.18 0.02 0.21 -0.04 0.21 0.10 -0.22 0.29 0.41
3966 11.10.6 -0.14 0.24 0.07 -0.10 1.06 -0.43 0.03 0.67 0.25 -0.11 0.40 0.74 0.02 0.86
3998 12.10.18 -0.25 -0.38 0.09 0.11 -0.20 0.07 0.03 -0.32 -0.17 0.17 0.65 -0.16 -0.14 0.22
4081 9.12.1 -0.92 -0.24 -0.34 -0.05 0.80 0.15 0.02 0.05 -0.01 0.23 -0.65 0.24 -0.50 0.70
4236 12.13.16 1.09 1.18 -0.13 -0.16 -0.29 0.25 0.04 0.47 0.25 -0.58 0.72 -1.79 -3.72 0.00
4270 10.14.10 -0.23 -1.08 -0.13 -0.33 -0.32 -0.08 0.04 -0.16 -0.25 0.25 -0.38 -1.08 0.09 0.03
4432 10.16.12 0.03 -0.90 0.17 0.04 -0.21 0.02 0.00 -0.15 -0.16 0.36 0.30 -0.62 0.27 0.03
4494 9.17.14 0.07 0.26 0.16 -0.12 0.47 -0.04 0.05 -0.23 0.13 -0.13 -0.09 0.57 0.20 0.01
4518 10.17.18 0.59 0.89 0.27 -0.31 0.63 1.21 0.03 0.33 0.62 -0.23 -0.70 -0.78 -1.05 0.14
4617 11.18.17 -0.07 -0.74 0.00 -0.01 -0.27 0.07 0.01 -0.07 -0.05 0.26 -0.33 -0.88 0.13 0.00
4654 9.19.14 0.03 0.09 -0.19 4.58 -0.53 0.83 0.02 0.40 0.93 0.06 1.12 5.87 0.66 0.49
4861 16.1.1 -0.34 0.10 0.08 0.09 -0.24 -0.33 0.05 -0.19 0.42 0.36 1.00 0.32 0.13 0.02
4875 16.1.15 -0.07 -0.16 0.14 0.25 0.06 0.08 0.04 -0.25 -0.01 0.19 0.18 -0.02 -0.06 0.12
4891 13.2.11 0.00 0.30 -0.09 -0.15 0.12 -0.19 0.01 0.00 0.01 -0.23 0.25 0.30 -0.18 0.10
5047 13.4.7 -1.37 0.22 0.97 1.46 0.43 0.82 0.00 -1.24 -0.79 -0.17 0.32 -0.68 -0.78 0.04
5048 13.4.8 -0.93 -0.08 -0.06 0.12 -0.32 -0.38 0.01 -0.40 -0.28 0.40 1.43 0.55 0.23 0.09
5050 13.4.10 -4.36 -1.59 -0.07 0.33 -1.01 -1.11 0.03 -3.37 -1.34 -0.37 1.52 1.39 0.86 0.00
5088 15.4.8 -2.15 -0.84 -0.06 0.07 -0.72 -1.00 0.00 -2.92 -0.71 0.11 1.68 0.28 0.69 0.00
5120 16.4.20 -0.08 -0.09 0.02 0.53 0.23 0.18 0.00 -0.19 -0.12 0.16 -0.28 -0.07 -0.26 0.26
5123 13.5.3 -0.37 -0.55 -0.15 0.05 -0.31 -0.12 0.02 -0.30 -0.32 0.11 0.13 -0.18 0.19 0.02
5228 14.6.8 -0.21 0.21 -0.41 -1.11 0.22 -0.35 0.04 -0.40 -0.05 -0.33 -0.25 0.61 -0.22 0.03
5264 16.6.4 -0.12 0.26 0.05 -0.03 0.08 -0.23 0.04 0.06 -0.05 -0.04 -0.05 0.25 0.06 0.51
5289 13.7.9 0.65 1.28 -0.25 0.19 -0.15 0.11 0.00 0.43 0.78 -0.58 1.14 0.34 -2.04 0.00
5290 13.7.10 0.17 0.12 0.09 0.08 -0.03 -0.14 0.04 0.01 0.03 0.02 0.00 -0.03 0.02 0.99
5296 13.7.16 0.75 1.15 -1.80 1.13 0.60 1.33 0.04 0.43 0.70 -0.70 1.16 -0.14 -1.85 0.10
5310 14.7.10 -0.01 -0.90 -0.13 -0.13 -0.30 -0.05 0.01 -0.20 -0.24 0.08 -0.36 -0.86 0.00 0.03
5345 16.7.5 -0.17 0.02 0.00 -0.33 0.42 -0.33 0.05 0.31 0.03 0.07 0.39 0.56 0.20 0.88
5408 15.8.8 0.08 0.32 0.06 -0.10 -0.13 -0.22 0.01 0.24 0.22 0.08 0.31 0.11 -0.22 0.19
5466 14.9.6 0.31 -0.11 0.32 0.30 0.00 0.27 0.05 0.24 0.16 0.24 0.15 -0.38 0.25 0.11
5519 16.9.19 0.45 0.53 -0.02 0.04 -0.04 -0.02 0.01 0.33 0.18 0.21 0.26 -0.26 -1.03 0.00
5531 13.10.11 -0.27 0.09 -0.13 -1.43 0.40 0.01 0.01 0.20 2.73 0.34 0.00 0.27 -0.11 0.03





Table 4.2 continued. 
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Spot ID 0_B 1.5_B 3_B 6_B 12_B 24_B p_B 0_CHX 1.5_CHX 3_CHX 6_CHX 12_CHX 24_CHX p_CHX
5564 15.10.4 0.24 -0.30 0.28 0.19 -0.09 0.25 0.04 0.15 0.19 0.35 0.10 -0.60 0.33 0.05
5583 16.10.3 -0.02 -0.42 0.10 0.02 -0.03 0.11 0.05 0.10 0.00 0.17 -0.19 -0.50 0.12 0.04
5600 16.10.20 0.53 1.07 -0.20 0.07 0.04 0.65 0.02 0.55 0.02 -1.04 0.20 -0.91 -0.48 0.03
5606 13.11.6 -0.24 -1.01 -0.31 -0.27 -0.29 -0.41 0.04 -0.20 -0.33 0.06 -0.48 -0.67 0.16 0.00
5780 13.13.20 -0.22 0.36 -2.20 -1.53 -0.71 0.08 0.03 0.27 0.65 -0.32 0.88 0.13 -0.56 0.53
5888 15.14.8 0.05 -0.73 -0.01 -0.06 -0.28 -0.03 0.01 -0.05 -0.01 0.25 -0.18 -0.78 0.19 0.03
5899 15.14.19 -0.44 -0.07 0.14 -2.21 0.11 -0.21 0.01 -0.09 -0.12 -0.02 -0.73 0.45 -0.30 0.30
5936 13.15.16 0.00 -0.07 0.25 0.02 -0.12 -0.05 0.01 0.06 0.04 0.14 0.06 -0.01 0.16 0.61
5952 14.15.12 -0.17 -0.81 -0.06 -0.17 -0.34 -0.20 0.03 -0.24 -0.19 0.12 -0.30 -0.72 0.07 0.05
6001 13.16.1 -0.04 0.06 -0.16 -0.39 0.07 -0.17 0.02 -0.11 0.11 -0.08 0.03 0.22 -0.04 0.06
6007 13.16.7 -0.45 -0.66 -0.50 -2.60 -0.27 -1.41 0.01 -0.24 1.48 0.10 0.94 0.72 1.21 0.59
6096 13.17.16 0.29 -0.12 0.37 0.21 0.10 0.32 0.02 0.10 0.19 0.42 0.05 -0.38 0.28 0.04
6130 15.17.10 -0.14 -0.61 0.15 0.06 -0.02 0.09 0.01 -0.15 -0.03 0.25 -0.35 -0.67 -0.01 0.01
6173 13.18.13 0.85 1.67 0.77 0.39 0.44 4.08 0.02 0.55 0.27 -0.35 0.76 -0.45 -0.55 0.12
6222 16.18.2 0.05 -0.64 0.08 0.03 -0.11 0.00 0.03 0.03 -0.02 0.34 -0.14 -0.65 0.14 0.02
6552 20.2.12 -0.13 0.04 -0.18 -0.28 -0.30 -0.02 0.03 -0.08 0.07 0.17 0.34 0.29 0.33 0.29
6585 18.3.5 -0.10 0.36 -0.34 -0.25 -0.13 -0.18 0.03 -0.02 0.11 0.02 0.43 0.48 0.08 0.06
6677 18.4.17 -0.15 0.38 -0.15 -0.10 0.19 -0.23 0.00 0.02 -0.03 -0.15 -0.29 0.49 -0.10 0.12
6695 19.4.15 -0.12 0.67 0.06 -0.36 -0.02 -0.09 0.04 0.06 -0.06 -0.01 -0.18 0.12 -0.13 0.79
6848 19.6.8 -0.13 0.17 -0.07 -0.09 0.19 0.11 0.04 -0.05 0.04 -0.06 0.45 0.42 -0.03 0.17
6854 19.6.14 0.13 -0.30 -0.85 -0.45 2.55 -0.52 0.01 -0.50 -0.38 -0.24 -0.12 0.86 -0.46 0.04
6867 20.6.7 -0.06 -0.49 0.05 0.01 -0.11 0.02 0.01 0.03 -0.03 0.27 -0.27 -0.46 0.04 0.04
6917 18.7.17 0.06 -0.10 0.03 0.17 0.12 0.49 0.02 0.19 -0.03 0.15 0.14 -0.26 -0.03 0.16
7050 17.9.10 -0.25 0.42 -0.18 -0.42 -0.20 -0.28 0.04 -0.51 0.00 0.12 0.30 0.35 0.11 0.20
7068 18.9.8 0.15 0.47 0.17 0.01 -0.21 -0.14 0.02 0.33 0.31 0.14 0.48 0.52 0.54 0.46
7097 19.9.17 0.01 -0.65 0.06 -0.09 -0.22 0.05 0.03 -0.10 -0.12 0.30 -0.24 -0.73 0.18 0.01
7128 17.10.8 0.87 0.54 0.33 0.67 5.54 1.25 0.00 0.55 1.34 -0.98 0.95 -0.29 -1.10 0.24
7154 18.10.14 -0.35 -1.31 -0.33 -0.34 -0.56 0.33 0.04 -0.41 -0.95 0.05 -0.63 -0.73 -0.15 0.30
7284 17.12.4 -0.12 0.15 -0.05 0.00 0.18 -0.13 0.02 -0.06 0.15 -0.02 0.09 -0.07 0.20 0.20
7346 20.12.6 -0.04 0.21 -0.01 -0.05 -0.08 -0.17 0.02 0.16 -0.04 -0.06 -0.09 0.18 0.05 0.44
7450 17.14.10 -0.02 -0.68 0.04 -0.04 -0.32 0.02 0.04 -0.14 -0.15 0.25 -0.26 -0.51 0.17 0.02
7468 18.14.8 0.10 -0.69 0.06 0.02 -0.29 -0.11 0.01 -0.13 -0.21 0.21 -0.11 -0.21 0.12 0.26
7490 19.14.10 -0.03 -0.65 0.03 0.00 -0.22 -0.03 0.02 -0.15 -0.11 0.28 -0.21 -0.73 0.22 0.02
7619 17.16.19 1.21 0.46 2.20 -0.10 0.66 1.77 0.05 2.67 0.77 -0.36 -0.16 0.85 0.02
7659 19.16.19 0.05 -0.74 0.09 0.05 -0.17 0.02 0.03 -0.12 -0.10 0.28 -0.28 -0.64 0.25 0.04
7664 20.16.4 0.02 0.18 -0.02 0.07 0.17 -0.08 0.01 0.06 0.09 0.03 0.09 0.28 0.06 0.29
7709 18.17.9 -0.08 0.09 -1.17 -0.31 1.64 -0.13 0.02 -0.31 0.26 0.05 -0.07 0.32 0.78 0.67
7739 19.17.19 1.07 0.91 0.43 -0.90 0.45 -0.38 0.04 0.61 0.22 -0.71 1.76 0.70 0.09
7782 18.18.2 0.18 0.17 0.29 0.30 -0.02 0.04 0.04 0.19 0.14 0.10 0.19 -0.07 0.30 0.33
8159 24.2.19 0.21 0.74 -0.76 -1.34 -0.26 1.65 0.02 0.53 0.47 0.22 1.37 1.09 1.11 0.68
8212 23.3.12 0.27 0.56 1.00 0.46 0.74 3.75 0.02 2.97 0.78 0.24 0.94 0.29 -0.38 0.92
8215 23.3.15 -0.02 -0.47 -0.01 -0.04 -0.14 -0.10 0.05 -0.12 -0.16 0.14 -0.25 -0.57 -0.01 0.01
8302 24.4.2 0.52 0.76 0.20 0.13 0.85 3.53 0.02 1.13 0.73 -1.00 0.27 -1.16 -0.28 0.40
8331 21.5.11 0.24 0.18 -0.13 -0.09 -0.15 -0.09 0.02 0.25 0.30 0.04 0.18 -0.04 0.01 0.20
8409 21.6.9 -0.17 -0.31 0.02 0.25 0.04 0.19 0.02 -0.33 -0.18 0.20 0.13 -0.16 -0.08 0.19
8427 22.6.7 0.11 -0.51 0.13 0.10 -0.15 -0.01 0.01 -0.06 -0.06 0.20 -0.10 -0.48 0.25 0.03
8436 22.6.16 -0.20 0.01 -1.10 -0.22 0.39 0.31 0.00 0.13 0.53 -0.28 1.94 0.58 -0.13 0.38
8450 23.6.10 0.06 0.01 -0.89 -0.46 1.57 0.53 0.01 -0.17 0.38 0.13 -0.32 2.52 0.20
8535 23.7.15 0.79 2.40 0.54 0.60 0.45 1.21 0.01 2.60 1.55 0.83 1.02 1.61 2.27 0.81
8555 24.7.15 0.36 -0.58 0.05 0.34 0.16 0.78 0.02 0.20 0.04 0.44 0.68 -0.17 0.62 0.30









Spot ID 0_B 1.5_B 3_B 6_B 12_B 24_B p_B 0_CHX 1.5_CHX 3_CHX 6_CHX 12_CHX 24_CHX p_CHX
8624 24.8.4 -0.17 -0.11 -0.18 -0.39 0.26 -0.92 0.04 -0.50 -0.46 0.19 -0.39 0.33 0.40 0.54
8644 21.9.4 0.40 0.73 0.04 0.12 -0.06 -0.15 0.04 0.08 -0.20 -0.60 0.63 -0.23 0.38 0.12
8664 22.9.4 0.33 -0.30 0.29 0.29 0.04 0.29 0.04 0.10 0.07 0.29 0.20 -0.44 0.22 0.03
8666 22.9.6 0.12 -0.48 0.23 0.15 -0.09 0.02 0.03 0.04 0.05 0.33 0.01 -0.42 0.29 0.03
8797 24.10.17 -0.09 0.50 1.60 0.53 -1.34 -0.37 0.03 0.50 2.92 1.71 -0.14 0.54 0.54
8859 23.11.19 0.00 0.07 -0.41 -0.15 0.73 0.24 0.03 -0.59 0.47 0.39 -0.22 0.58 0.36 0.09
8869 24.11.9 3.90 1.77 0.22 0.83 2.33 0.04 1.12 2.02 -0.18 -0.61 -1.57 0.10
8883 21.12.3 -0.07 -0.41 -0.11 0.03 -0.04 0.00 0.02 -0.17 -0.08 0.12 -0.18 -0.28 0.30 0.00
8903 22.12.3 0.27 -0.40 0.25 0.56 1.46 1.01 0.03 0.52 -0.29 0.46 1.21 -0.38 1.14 0.10
8964 21.13.4 1.51 -1.13 -3.28 -1.18 0.45 0.75 0.05 -0.36 0.63 -2.29 -0.11 -0.54 -1.61 0.24
9067 22.14.7 0.01 -0.42 0.02 0.04 -0.23 0.03 0.04 -0.12 -0.16 0.17 -0.13 -0.39 0.09 0.02
9202 21.16.2 0.01 0.18 -0.21 -0.20 0.08 -0.32 0.02 0.01 -0.04 -0.17 0.09 0.35 0.04 0.02
9208 21.16.8 0.05 -0.15 0.04 0.09 -0.12 -0.02 0.04 -0.01 -0.02 0.13 0.20 -0.12 0.23 0.06
9246 23.16.6 -0.28 1.04 -1.16 0.06 -0.82 0.03 -0.01 1.73 0.67 0.02 -0.04 0.21 0.88
9252 23.16.12 0.19 -0.07 0.26 0.21 0.00 0.10 0.04 0.12 0.16 0.29 0.06 -0.22 0.27 0.03
9279 24.16.19 -0.38 -1.70 -0.71 0.47 -0.20 0.14 0.01 -0.63 -0.73 -0.13 -0.05 -1.65 -0.14 0.00
9314 22.17.14 -0.37 -0.24 -0.34 -0.20 0.01 0.00 0.00 -0.33 -0.26 -0.14 -0.17 -0.07 -0.19 0.46
9382 22.18.2 0.13 -0.17 0.19 0.04 -0.11 0.04 0.01 0.06 0.12 0.21 0.06 -0.16 0.15 0.31
9396 22.18.16 0.06 -0.50 0.13 0.07 -0.16 0.02 0.01 -0.05 -0.02 0.24 -0.13 -0.50 0.14 0.02
9779 25.3.19 0.03 -0.54 0.11 0.11 -0.06 0.07 0.01 -0.03 0.00 0.24 -0.05 -0.38 0.14 0.04
9792 26.3.12 -0.01 -0.34 0.08 -0.03 -0.16 0.20 0.04 -0.09 -0.06 0.21 -0.10 -0.27 0.06 0.09
9837 28.3.17 0.08 -0.23 0.17 0.07 -0.06 0.06 0.03 0.14 0.15 0.26 0.30 -0.11 0.30 0.48
9873 26.4.13 0.02 -0.32 0.05 0.09 -0.22 0.20 0.02 0.08 -0.02 0.18 0.02 -0.24 0.13 0.38
9928 25.5.8 -0.15 -0.43 -0.04 0.11 -0.11 0.10 0.05 -0.12 -0.04 0.16 -0.08 -0.30 0.07 0.08
9955 26.5.15 -0.01 -0.30 0.05 0.00 -0.26 0.10 0.01 0.01 -0.05 0.17 -0.07 -0.16 0.10 0.40
9956 26.5.16 -0.04 -0.22 0.00 -0.01 -0.26 -0.10 0.04 0.15 -0.01 0.12 0.06 -0.13 0.16 0.66
9976 27.5.16 -0.05 -0.67 -0.02 -0.04 -0.14 -0.02 0.00 -0.13 -0.12 0.14 -0.32 -0.61 0.26 0.04
9987 28.5.7 -0.05 -0.43 -0.02 -0.01 -0.17 -0.05 0.05 -0.05 0.06 0.13 0.02 -0.22 0.09 0.07
10038 26.6.18 -0.41 0.15 -1.30 -0.31 0.74 0.08 0.02 -0.25 -2.29 -0.19 0.01 0.28 -0.27 0.65
10040 26.6.20 -0.29 -0.05 -0.33 0.30 0.49 0.16 0.04 -0.07 -0.02 -0.29 -0.13 0.27 -0.70 0.02
10065 28.6.5 -0.14 -0.60 -0.03 -0.11 -0.22 -0.09 0.05 -0.13 -0.08 0.24 -0.08 -0.45 0.13 0.04
10086 25.7.6 0.23 0.27 -0.81 -0.47 0.90 0.56 0.05 0.01 0.90 0.28 1.58 1.20 0.16 0.09
10110 26.7.10 0.00 -0.51 0.04 0.02 -0.27 0.01 0.01 -0.19 -0.12 0.17 -0.18 -0.36 0.08 0.03
10138 27.7.18 -0.30 -0.06 -0.22 -0.31 -0.06 0.10 0.04 -0.13 -0.08 -0.17 0.06 0.25 0.35 0.03
10251 25.9.11 -0.01 -1.00 0.28 0.21 -0.14 -0.19 0.02 -0.20 -0.21 0.30 -0.16 -0.63 0.27 0.12
10261 26.9.1 0.12 -0.55 0.07 0.16 -0.13 0.04 0.01 0.06 0.02 0.22 -0.06 -0.33 0.16 0.13
10270 26.9.10 -0.01 1.06 -0.47 -0.12 0.01 1.74 0.02 -0.27 -0.14 0.28 1.18 0.39 -0.34 0.41
10273 26.9.13 0.17 -0.26 0.16 0.23 -0.16 0.35 0.01 0.02 0.20 0.25 0.10 -0.25 0.20 0.24
10275 26.9.15 0.07 -0.50 0.17 0.15 -0.17 0.10 0.02 0.07 0.05 0.26 -0.03 -0.35 0.20 0.16
10333 25.10.13 0.89 0.90 -0.71 0.33 1.32 2.84 0.03 1.75 0.59 -1.59 -0.17 0.51
10336 25.10.16 -0.05 -0.61 0.00 0.02 -0.11 -0.09 0.03 -0.05 -0.10 0.21 -0.11 -0.41 0.19 0.04
10351 26.10.11 -0.34 -0.33 -0.73 -0.79 -0.01 -0.28 0.01 -1.12 -0.31 0.01 -0.21 -0.10 -0.20 0.11
10426 26.11.6 0.04 -0.27 0.10 0.05 -0.18 0.02 0.02 -0.16 -0.16 0.06 -0.13 -0.09 0.03 0.27
10430 26.11.10 -0.09 -1.03 -0.08 -0.21 -0.35 -0.38 0.05 0.16 -0.02 0.26 0.03 -0.13 0.13 0.75
10474 28.11.14 -0.10 2.27 -0.48 0.65 8.04 0.33 0.00 -0.14 0.47 -0.18 0.76 0.62 0.11
10500 25.12.20 -0.28 1.26 0.00 0.59 1.17 8.05 0.01 0.21 0.69 -0.02 1.02 1.72 -1.59 0.45
10535 27.12.15 -0.32 0.70 0.02 -0.19 -0.24 -0.11 0.02 0.11 -0.07 -0.06 0.60 0.34 0.60 0.20
10652 25.14.12 -0.19 -0.88 -0.08 -0.14 -0.30 -0.27 0.02 -0.25 -0.30 0.11 -0.41 -0.54 0.08 0.04
10656 25.14.16 -0.17 -0.53 -0.01 -0.07 -0.13 -0.12 0.02 -0.24 -0.24 0.12 -0.19 -0.10 0.04 0.44
10737 25.15.17 0.06 -0.21 -0.02 0.04 -0.05 0.03 0.02 -0.02 0.07 0.21 0.04 -0.04 0.16 0.62








Spot ID 0_B 1.5_B 3_B 6_B 12_B 24_B p_B 0_CHX 1.5_CHX 3_CHX 6_CHX 12_CHX 24_CHX p_CHX
10812 25.16.12 -0.02 -0.62 0.18 0.07 -0.12 0.09 0.00 -0.06 -0.15 0.28 -0.24 -0.46 0.09 0.05
10823 26.16.3 0.12 -0.22 -0.03 0.00 -0.13 0.23 0.02 -0.08 0.04 0.09 0.05 -0.05 0.05 0.56
10837 26.16.17 -0.15 0.41 -0.10 -0.10 -0.14 0.32 0.03 0.01 -0.03 -0.01 -0.02 -0.07 0.08 0.87
10852 27.16.12 0.14 -0.29 0.12 0.09 -0.10 0.05 0.00 -0.03 0.05 0.24 -0.11 -0.34 0.10 0.01
10861 28.16.1 -0.19 -0.56 -0.13 -0.06 -0.22 -0.23 0.04 -0.31 -0.22 0.16 -0.20 -0.49 0.05 0.02
10869 28.16.9 0.72 0.39 -0.62 -0.26 -0.94 3.15 0.03 0.33 -0.85 0.02 1.22 1.44 2.38 0.15
11027 28.18.7 -0.14 -0.60 -0.02 -0.11 -0.16 0.04 0.05 0.10 -0.01 0.20 -0.18 -0.54 0.19 0.02
11076 26.19.16 0.03 -0.79 0.02 -0.10 -0.23 0.38 0.03 -0.07 -0.09 0.17 -0.31 -0.69 0.16 0.04
11262 32.1.2 -0.16 -0.48 0.00 0.14 -0.11 -0.08 0.01 -0.32 -0.22 0.09 0.02 -0.38 0.21 0.00
11297 29.2.17 0.10 0.42 0.12 0.07 0.39 0.14 0.02 0.07 0.10 -0.13 -0.38 0.36 -0.02 0.47
11404 31.3.4 -0.04 0.32 -0.31 -0.08 0.12 -0.09 0.01 0.09 0.15 -0.06 0.53 0.39 0.17 0.01
11477 30.4.17 -0.04 -0.37 0.02 0.03 -0.25 0.02 0.02 -0.09 -0.08 0.14 -0.09 -0.37 0.08 0.12
11481 31.4.1 0.01 -0.56 0.06 0.11 -0.18 -0.02 0.01 -0.06 -0.03 0.25 0.03 -0.54 0.17 0.04
11505 32.4.5 1.00 0.99 0.01 0.32 0.29 0.05 0.05 1.37 0.26 -0.16 0.24 -0.27 -1.84 0.00
11549 30.5.9 -0.10 -0.39 -0.15 -0.02 -0.26 0.02 0.03 0.08 -0.04 0.13 -0.06 -0.33 0.10 0.02
11576 31.5.16 0.03 -0.46 0.02 0.01 -0.11 -0.04 0.03 -0.10 -0.04 0.21 -0.16 -0.53 0.13 0.01
11581 32.5.1 -0.10 0.40 0.08 -0.02 0.12 -0.13 0.01 0.07 -0.07 -0.05 0.04 0.09 -0.11 0.53
11599 32.5.19 -0.05 0.22 -0.04 -0.06 0.04 -0.24 0.02 -0.06 -0.03 -0.07 -0.08 0.19 0.02 0.31
11644 31.6.4 0.19 0.39 0.17 0.23 0.04 -0.10 0.00 0.17 0.37 0.22 0.57 0.26 0.43 0.19
11741 32.7.1 -0.30 0.41 0.05 0.13 0.08 -0.06 0.01 0.28 0.06 -0.11 -0.32 0.16 -0.51 0.20
11803 31.8.3 0.15 -0.38 0.22 0.11 -0.05 0.22 0.03 0.11 0.13 0.28 0.00 -0.41 0.22 0.14
11904 32.9.4 0.26 1.79 0.38 0.45 0.23 0.58 0.04 1.07 0.08 -0.28 0.84 1.19 0.11 0.41
11905 32.9.5 0.91 8.88 1.68 1.40 2.54 2.82 0.00 1.95 1.07 2.87 1.50 0.09 0.24
11909 32.9.9 -0.09 -0.53 0.05 0.04 -0.14 0.04 0.03 -0.13 -0.10 0.19 -0.13 -0.36 0.01 0.20
11924 29.10.4 -0.07 -0.77 0.02 -0.01 -0.34 -0.10 0.03 -0.15 -0.16 0.19 -0.33 -0.66 0.20 0.03
11943 30.10.3 0.23 -0.55 0.14 0.24 -0.02 0.17 0.04 0.06 0.07 0.29 -0.12 -0.43 0.26 0.22
12009 29.11.9 -0.12 0.16 0.09 -0.17 0.31 -0.33 0.01 -0.05 0.11 -0.02 0.12 0.34 0.16 0.05
12270 30.14.10 3.54 2.81 3.51 1.19 1.71 0.67 0.03 1.86 0.95 -0.69 1.96 0.48 1.45 0.20
12272 30.14.12 0.06 -0.54 -0.02 -0.08 -0.17 -0.06 0.04 -0.20 -0.04 0.14 -0.22 -0.52 0.08 0.05
12404 29.16.4 -0.06 -0.66 -0.09 -0.11 -0.24 -0.09 0.01 -0.23 -0.03 0.25 -0.21 -0.36 0.22 0.02
12405 29.16.5 0.01 -0.39 0.13 0.04 -0.11 0.15 0.01 -0.15 -0.16 0.15 -0.28 -0.41 0.11 0.03
12419 29.16.19 0.23 0.61 -0.10 0.27 1.41 0.05 0.02 0.98 0.23 0.35 0.36 1.00 -0.18 0.53
12474 32.16.14 0.13 -0.51 0.00 0.04 -0.04 0.04 0.02 -0.12 -0.10 0.13 -0.13 -0.64 -0.18 0.02
12638 32.18.18 0.12 -0.12 0.05 -0.29 -0.62 -0.17 0.04 -0.18 -0.24 0.02 0.23 0.01 0.12 0.23
12806 33.1.6 0.55 2.31 -0.69 0.04 -0.40 0.55 0.01 0.51 0.33 -0.58 1.13 -0.34 0.62 0.37
12816 33.1.16 -0.02 -0.15 -0.09 -0.03 -0.01 0.19 0.00 0.10 -0.05 -0.07 0.04 -0.02 0.17 0.09
12827 34.1.7 -0.06 0.25 -0.04 -0.07 0.11 -0.10 0.01 -0.06 0.01 -0.04 -0.01 0.23 -0.10 0.20
12844 35.1.4 -0.01 0.57 -0.21 -0.31 0.10 -0.18 0.00 -0.05 0.03 -0.05 0.19 0.41 -0.19 0.27
12871 36.1.11 0.12 -0.13 0.20 0.32 0.08 0.15 0.04 -0.09 0.02 0.16 0.26 -0.22 0.04 0.00
12878 36.1.18 -0.33 1.17 1.86 0.17 0.10 0.34 0.04 1.05 0.81 0.50 1.26 -0.44 -2.13 0.07
12909 34.2.9 0.60 3.14 0.76 0.08 0.88 0.93 0.04 0.71 1.03 -0.52 1.36 -0.13 -0.41 0.39
13016 35.3.16 0.00 -0.56 -0.02 0.00 -0.22 -0.12 0.04 -0.12 0.00 0.13 -0.20 -0.64 0.15 0.01
13031 36.3.11 0.01 -0.55 -0.11 -0.05 -0.18 -0.05 0.01 -0.12 -0.11 0.11 -0.05 -0.53 -0.01 0.03
13033 36.3.13 -0.05 1.50 -0.76 -0.68 0.17 0.44 0.03 -0.24 -0.46 -0.65 -0.02 -0.02 -1.31 0.73
13034 36.3.14 0.15 -0.19 0.04 0.02 -0.07 0.02 0.05 -0.02 -0.01 0.16 0.00 -0.20 0.05 0.13
13101 36.4.1 0.59 3.74 0.50 0.09 0.25 1.43 0.01 0.75 0.36 0.68 0.59 -0.38 -1.24 0.30
13150 34.5.10 0.38 1.34 -0.98 -0.18 0.36 0.51 0.02 0.44 0.76 0.68 0.59 0.10 0.06 0.90
13155 34.5.15 -0.03 -0.42 -0.04 0.05 -0.20 0.00 0.03 -0.15 -0.08 0.20 -0.20 -0.35 0.07 0.09
13166 35.5.6 1.00 2.93 -0.14 1.04 0.26 0.73 0.04 2.40 0.85 0.40 3.01 0.33 1.24 0.57
13221 34.6.1 -0.21 0.36 -0.18 -0.22 0.00 -0.33 0.03 -0.09 0.18 0.03 0.28 0.67 0.10 0.10








Spot ID 0_B 1.5_B 3_B 6_B 12_B 24_B p_B 0_CHX 1.5_CHX 3_CHX 6_CHX 12_CHX 24_CHX p_CHX
13330 35.7.10 -0.07 -0.39 -0.08 0.01 -0.23 0.03 0.04 -0.08 -0.16 0.11 -0.19 -0.35 -0.10 0.12
13362 33.8.2 -0.56 -0.34 -1.65 -1.90 -0.18 -0.49 0.04 -0.35 -0.14 -0.26 -0.18 0.22 0.79 0.88
13374 33.8.14 -0.07 -0.46 -0.04 -0.17 -0.07 -0.04 0.04 -0.07 0.14 0.08 -0.18 -0.31 0.10 0.07
13441 33.9.1 -0.03 0.22 -0.16 -0.10 0.01 -0.25 0.02 -0.05 -0.01 -0.15 0.06 0.28 0.12 0.19
13446 33.9.6 -0.03 -0.10 0.07 0.28 0.33 0.15 0.02 -0.27 -0.24 0.01 -0.21 -0.31 -0.25 0.13
13525 33.10.5 -0.20 -0.73 -0.29 -0.06 -0.21 0.12 0.02 -0.14 -0.17 0.00 -0.35 -0.46 -0.18 0.27
13554 34.10.14 0.00 1.76 0.77 0.91 0.05 1.03 0.03 1.18 1.58 -4.10 0.08 0.86 0.29 0.52
13583 36.10.3 0.12 -0.21 0.14 0.23 -0.07 -0.05 0.03 0.14 -0.07 0.19 0.06 -0.56 0.04 0.00
13654 35.11.14 -0.19 -1.71 -0.09 -0.08 -0.32 -0.52 0.01 -0.65 -0.64 0.17 -0.72 -0.70 -0.22 0.21
13683 33.12.3 0.29 1.95 -1.20 0.06 2.44 1.59 0.04 0.62 0.10 -0.19 1.63 0.80 -1.06 0.59
13892 35.14.12 -0.02 -0.68 -0.05 -0.10 -0.29 -0.09 0.05 -0.07 -0.02 0.20 -0.14 -0.69 0.02 0.04
13914 36.14.14 -0.27 -0.80 -0.14 -0.14 -0.29 -0.14 0.03 -0.25 -0.35 0.12 -0.36 -0.88 0.08 0.01
13937 33.15.17 -0.03 -0.57 0.00 -0.01 -0.22 -0.11 0.03 -0.12 -0.06 0.18 -0.13 -0.28 0.10 0.05
13939 33.15.19 -0.27 -0.23 0.04 0.06 -0.01 -0.11 0.04 -0.19 0.13 0.02 0.13 -0.11 0.08 0.14
13987 36.15.7 0.13 0.33 0.04 0.12 0.13 -0.01 0.03 0.23 0.24 0.03 0.14 0.23 -0.11 0.08
14010 33.16.10 -0.05 0.01 -0.03 -0.33 1.34 -0.10 0.00 0.04 0.43 -0.14 0.57 0.29 -0.03 0.53
14014 33.16.14 -0.13 -0.41 -0.03 -0.03 -0.18 -0.11 0.03 -0.15 -0.04 0.10 -0.13 -0.18 0.06 0.14
14020 33.16.20 0.00 -0.38 0.10 0.07 -0.10 -0.03 0.02 -0.05 -0.09 0.18 -0.13 -0.24 0.17 0.03
14034 34.16.14 0.00 -0.90 -0.08 -0.08 -0.39 -0.13 0.02 -0.21 -0.12 0.10 -0.39 -0.85 0.14 0.01
14069 36.16.9 -0.04 0.07 -0.19 -0.21 0.08 -0.23 0.01 0.06 -0.02 0.02 -0.03 -0.08 -0.04 0.83
14182 34.18.2 0.87 1.34 0.46 0.12 2.56 0.07 0.03 1.83 1.55 0.87 2.39 1.47 1.10 0.63
14183 34.18.3 -0.08 0.47 0.06 -0.24 0.13 -0.31 0.05 -0.06 0.27 0.12 0.70 0.57 0.45 0.78
14186 34.18.6 -0.02 -0.87 -0.07 -0.04 -0.29 0.04 0.03 -0.05 -0.06 0.29 -0.30 -0.86 0.11 0.03
14217 35.18.17 0.18 -0.28 0.20 0.04 -0.05 0.19 0.01 0.05 0.13 0.26 0.03 -0.24 0.21 0.18
14454 39.1.14 -0.11 0.14 -0.11 -0.09 0.14 -0.08 0.02 0.00 -0.04 -0.11 -0.03 0.38 -0.03 0.07
14463 40.1.3 0.06 -0.23 0.07 0.11 0.01 0.09 0.02 -0.04 -0.01 0.02 -0.18 -0.19 -0.09 0.52
14587 38.3.7 0.01 -0.18 -0.50 0.95 1.54 -0.37 0.03 -0.12 0.46 0.16 -2.33 0.13 -0.23 0.38
14616 39.3.16 -0.11 -0.28 0.06 0.17 -0.09 0.00 0.04 -0.17 -0.04 0.11 0.02 -0.25 0.04 0.20
14636 40.3.16 -0.03 -0.44 -0.07 -0.16 -0.14 -0.11 0.04 -0.20 -0.09 0.07 -0.02 -0.27 0.03 0.02
14639 40.3.19 0.03 -0.28 0.04 0.01 0.01 0.15 0.03 -0.04 -0.03 0.17 -0.13 -0.26 0.08 0.02
14641 37.4.1 -0.39 -0.50 -0.01 0.06 0.12 0.32 0.00 -0.38 -0.01 0.22 0.36 -0.22 -0.01 0.04
14704 40.4.4 -0.07 -0.63 -0.03 -0.08 -0.06 -0.15 0.01 -0.05 -0.14 0.01 -0.24 -0.72 0.08 0.01
14723 37.5.3 -0.16 -0.71 -0.09 -0.17 -0.21 -0.10 0.03 -0.21 -0.21 0.11 -0.27 -0.43 0.07 0.07
14730 37.5.10 0.36 -0.06 0.01 -0.08 -0.17 0.13 0.05 0.30 0.07 0.15 -0.09 -0.34 -0.17 0.11
14755 38.5.15 -0.15 -0.62 -0.08 -0.12 -0.25 -0.17 0.05 -0.24 -0.15 0.22 -0.27 -0.44 0.08 0.02
14756 38.5.16 -0.08 -0.54 -0.09 -0.09 -0.15 -0.07 0.05 -0.12 -0.08 0.23 -0.24 -0.47 0.08 0.01
14759 38.5.19 -0.04 0.09 -0.02 -0.03 -0.14 -0.24 0.05 -0.04 0.05 0.04 0.13 0.14 0.17 0.38
14822 38.6.2 0.13 0.28 0.02 0.26 0.07 0.03 0.04 0.16 0.08 0.13 0.16 0.34 0.09 0.51
14869 40.6.9 0.02 -0.36 0.03 -0.04 -0.09 -0.01 0.02 -0.04 0.01 0.15 0.07 -0.15 0.16 0.25
14889 37.7.9 0.01 -1.68 -0.75 -0.49 0.27 -0.39 0.02 -0.17 -0.11 0.19 0.30 -0.48 0.74 0.45
14912 38.7.12 0.10 -0.50 -0.10 0.02 -0.02 -0.09 0.01 -0.23 -0.19 0.06 -0.33 -0.49 0.02 0.03
14930 39.7.10 -0.07 -0.68 -0.15 -0.20 -0.24 -0.19 0.02 -0.17 -0.16 0.11 -0.12 -0.72 0.15 0.01
14973 37.8.13 0.11 -0.33 0.08 0.13 -0.07 0.15 0.03 0.02 0.05 0.15 0.27 -0.12 0.16 0.28
14992 38.8.12 -0.09 -0.68 0.04 -0.03 -0.08 -0.08 0.02 -0.15 -0.11 0.22 -0.22 -0.62 0.11 0.05
15057 37.9.17 -0.28 -0.43 0.01 0.29 0.10 0.05 0.05 -0.25 -0.10 0.22 -0.01 -0.34 0.12 0.16
15058 37.9.18 0.13 -0.55 0.11 0.03 -0.07 0.07 0.01 0.02 0.01 0.18 -0.14 -0.56 0.08 0.00
15089 39.9.9 -0.07 0.32 0.18 0.13 -0.01 -0.16 0.05 0.00 0.02 -0.04 0.04 0.21 -0.02 0.38
15092 39.9.12 -0.09 0.17 -0.19 -0.14 -0.08 -0.13 0.04 0.03 0.04 0.04 0.34 0.35 0.31 0.01
15109 40.9.9 0.08 -0.24 0.14 0.12 0.00 -0.02 0.03 0.00 0.00 0.19 -0.01 -0.29 0.07 0.25
15145 38.10.5 -0.28 -0.73 -0.15 -0.16 -0.25 -0.24 0.04 -0.22 -0.27 0.11 -0.43 -0.60 -0.06 0.08









Spot ID 0_B 1.5_B 3_B 6_B 12_B 24_B p_B 0_CHX 1.5_CHX 3_CHX 6_CHX 12_CHX 24_CHX p_CHX
15222 38.11.2 0.40 1.24 0.12 0.52 0.37 0.79 0.05 0.62 -0.04 -0.53 -0.17 -0.14 -0.54 0.21
15263 40.11.3 -0.26 -1.84 -0.63 -0.18 -0.76 -0.95 0.01 -0.60 -0.39 -1.63 -0.08 -0.67 -0.11 0.61
15266 40.11.6 -0.13 -0.24 0.28 0.25 -0.01 -0.01 0.01 -0.15 -0.02 0.11 0.22 -0.24 -0.02 0.11
15281 37.12.1 -0.11 1.28 -1.20 0.27 0.42 -0.35 0.03 0.20 0.23 -0.23 1.49 1.29 -0.17 0.19
15282 37.12.2 -0.49 0.34 -0.30 -0.21 -0.22 -0.50 0.00 -0.78 0.51 0.31 0.89 0.74 0.14 0.00
15330 39.12.10 -0.53 0.01 -1.34 -0.51 0.42 -0.54 0.04 0.16 0.02 0.54 0.21 0.74 -0.37 0.82
15430 40.13.10 -0.11 -0.51 -0.09 -0.11 -0.17 -0.08 0.02 -0.10 -0.12 0.05 -0.26 -0.55 0.12 0.00
15447 37.14.7 -0.51 0.00 -0.14 -0.34 0.02 -0.25 0.02 0.02 0.35 0.18 -0.08 0.22 -0.12 0.04
15569 39.15.9 -0.23 -0.55 -0.09 0.00 -0.20 -0.09 0.03 -0.26 -0.19 0.08 -0.19 -0.43 0.08 0.07
15608 37.16.8 0.16 0.14 -0.24 -0.26 -0.41 -0.05 0.04 0.17 0.38 0.00 0.50 0.36 0.27 0.37
15663 40.16.3 -0.75 6.52 0.05 -0.94 1.32 -0.99 0.04 0.70 -0.12 0.01 -0.14 -0.99 0.93
15751 40.17.11 0.05 -0.38 -0.11 -0.02 -0.03 -0.06 0.05 -0.09 -0.16 -0.01 -0.23 -0.25 0.00 0.62
15774 37.18.14 0.68 3.69 -0.30 -0.66 -0.01 0.66 0.02 0.32 0.26 -0.06 0.60 0.01 -0.37 0.82
16043 43.1.3 -0.08 -0.55 0.02 0.04 -0.10 0.01 0.00 -0.03 0.07 0.11 -0.20 -0.47 0.05 0.07
16045 43.1.5 -0.07 -0.32 0.01 0.00 -0.12 -0.01 0.03 -0.04 -0.03 0.05 -0.14 -0.29 -0.06 0.05
16053 43.1.13 -0.12 -0.09 -2.02 -1.11 -1.40 -0.25 0.02 -0.53 0.12 0.38 1.57 1.12 0.08 0.12
16061 44.1.1 -0.14 0.45 -0.56 -0.74 -0.35 -0.18 0.03 -0.41 -0.47 -0.14 -1.02 0.49 0.02 0.09
16124 43.2.4 -0.33 0.11 0.08 -0.10 -0.43 -0.17 0.00 -0.14 0.48 0.16 0.11 -0.34 -0.34 0.00
16177 41.3.17 0.28 2.55 -0.08 0.51 3.61 1.59 0.03 0.33 1.02 0.75 5.58 5.12 0.57 0.15
16211 43.3.11 -0.30 0.31 -0.58 -0.74 -0.05 0.20 0.04 -0.16 -0.24 -0.09 -0.91 0.20 -0.65 0.12
16256 41.4.16 -0.07 1.02 -0.11 -0.35 0.05 -0.04 0.02 0.18 -0.17 -0.02 -0.32 0.31 0.05 0.69
16259 41.4.19 -0.22 0.46 -0.02 -0.37 0.01 0.02 0.04 0.10 -0.11 -0.02 -0.43 0.07 -0.13 0.20
16271 42.4.11 0.04 -0.54 -0.02 -0.07 -0.10 -0.02 0.01 -0.09 -0.10 0.15 -0.17 -0.54 0.21 0.01
16273 42.4.13 0.04 -0.45 0.08 0.07 -0.08 0.13 0.00 -0.01 -0.07 0.15 -0.09 -0.43 0.04 0.08
16277 42.4.17 -0.04 0.47 0.10 0.01 0.05 0.12 0.03 0.10 0.01 -0.06 0.26 0.29 0.00 0.25
16278 42.4.18 -0.31 0.67 -0.13 -0.79 -0.24 0.33 0.04 -0.20 -0.27 -0.05 -0.67 -0.08 -0.01 0.40
16302 44.4.2 0.01 -0.48 -0.02 -0.03 0.02 0.08 0.00 -0.19 -0.02 0.18 -0.28 -0.59 -0.11 0.05
16340 41.5.20 -0.15 -0.78 -0.04 -0.26 -0.23 -0.07 0.01 -0.07 0.13 0.25 0.03 -0.41 0.14 0.05
16539 43.7.19 0.10 -0.28 -0.16 -0.10 0.11 -0.38 0.01 -0.19 -0.24 -0.32 -0.36 -0.01 -0.51 0.51
16577 41.8.17 0.17 2.61 0.02 -0.66 0.35 2.03 0.05 0.51 1.19 -0.07 0.91 1.11 -0.30 0.58
16595 42.8.15 0.14 -0.04 0.04 0.04 -0.07 0.01 0.03 0.07 0.03 0.09 0.05 -0.06 0.10 0.56
16599 42.8.19 -0.05 -0.37 0.02 0.04 -0.11 -0.11 0.03 0.00 -0.02 0.11 0.09 -0.27 0.08 0.02
16620 43.8.20 -0.20 -0.72 -0.19 -0.24 -0.14 0.02 0.05 -0.24 -0.20 0.10 -0.13 -0.55 0.31 0.02
16626 44.8.6 -0.45 -3.03 -0.50 -0.79 -1.54 0.21 0.00 -0.85 -0.28 -0.61 -0.77 -0.57 -1.25 0.75
16635 44.8.15 -0.13 -0.63 -0.03 -0.07 -0.10 -0.17 0.02 -0.16 -0.16 0.11 -0.24 -0.60 0.09 0.00
16694 43.9.14 -0.30 0.16 -0.51 -0.37 -0.23 -0.47 0.01 -0.08 0.05 -0.12 0.32 0.63 0.21 0.01
16719 44.9.19 0.59 0.82 0.05 -0.25 0.94 0.03 0.60 0.18 -0.02 0.51 -1.36 -1.98 0.43
16754 42.10.14 -0.12 -0.59 -0.07 -0.05 -0.09 -0.12 0.03 -0.08 -0.15 0.19 -0.20 -0.35 0.18 0.03
16776 43.10.16 0.18 -0.43 -0.03 0.13 -0.01 0.33 0.01 0.03 -0.19 0.11 -0.38 -0.88 -0.03 0.04
16802 41.11.2 0.64 0.89 -0.26 -0.94 0.22 0.01 0.60 0.16 -0.35 1.45 1.26 2.54 0.32
16837 42.11.17 -0.14 0.20 0.02 -0.02 -0.16 -0.33 0.02 0.01 0.06 0.16 0.23 0.17 0.15 0.75
16992 42.13.12 -0.13 -0.58 -0.07 -0.06 -0.19 -0.03 0.05 -0.10 -0.10 0.17 -0.21 -0.45 0.13 0.02
17169 43.15.9 -0.24 -0.60 -0.06 -0.08 -0.24 -0.11 0.04 -0.25 -0.15 0.21 -0.08 -0.42 0.04 0.03
17213 41.16.13 -0.08 -0.43 0.07 0.11 -0.02 0.02 0.04 0.10 0.16 0.20 -0.01 -0.42 0.15 0.02
17383 42.18.3 -0.10 -0.54 0.11 0.06 -0.13 0.05 0.04 -0.14 -0.19 0.21 -0.20 -0.42 0.10 0.23
17626 46.1.6 0.62 1.78 0.34 -0.09 0.53 0.56 0.01 0.82 0.58 -0.37 -0.28 -2.20 -2.37 0.01
17639 46.1.19 0.42 1.48 0.00 0.05 0.12 0.31 0.03 0.29 -0.35 -1.01 0.27 -0.61 -1.39 0.33
17645 47.1.5 0.68 1.28 0.23 0.04 0.14 0.07 0.02 0.07 -0.16 -0.67 0.47 -0.34 -0.46 0.19
17664 48.1.4 -0.08 0.28 -0.57 -0.41 -0.08 -0.14 0.04 -0.09 -0.45 -0.16 -0.32 0.10 -0.37 0.70
17816 47.3.16 -0.18 -0.54 -0.12 -0.18 -0.17 -0.11 0.04 -0.10 -0.07 0.19 -0.13 -0.44 0.14 0.00

















able 4.2 continued. 
 
Spot ID 0_B 1.5_B 3_B 6_B 12_B 24_B p_B 0_CHX 1.5_CHX 3_CHX 6_CHX 12_CHX 24_CHX p_CHX
17842 45.4.2 0.56 3.06 -0.21 0.35 0.17 0.87 0.02 0.01 0.24 -0.17 1.18 -0.27 0.85 0.07
17853 45.4.13 0.62 0.45 0.32 -0.04 0.28 -0.94 0.01 0.96 1.00 0.40 -0.18 -1.08 0.11 0.05
17877 46.4.17 0.07 0.26 -0.06 0.01 0.01 -0.02 0.02 0.07 0.00 -0.06 0.09 0.15 -0.06 0.27
17891 47.4.11 0.17 0.65 0.08 0.00 0.16 -0.10 0.05 -0.10 0.15 -0.05 -0.57 0.23 -0.15 0.23
17907 48.4.7 -0.15 3.68 -1.77 -0.60 -0.73 0.89 0.02 0.20 0.89 -0.59 0.93 -0.86 1.13 0.57
17968 47.5.8 -0.22 0.32 0.04 -0.67 -0.04 -0.22 0.03 -0.11 -0.34 -0.05 -0.44 0.17 -0.10 0.41
18126 47.7.6 0.38 4.40 -0.18 0.51 0.47 0.13 0.01 0.81 1.20 0.58 1.13 1.10 0.09 0.93
18157 48.7.17 0.43 2.02 -2.37 -2.55 6.62 -0.42 0.00 0.90 1.03 -0.02 0.24 1.74 0.47
18259 45.9.19 -0.02 -0.47 0.06 -0.01 -0.09 0.16 0.04 0.01 0.04 0.24 -0.03 -0.38 0.17 0.04
18279 46.9.19 -0.07 -0.50 0.11 -0.02 -0.17 -0.03 0.04 -0.06 -0.07 0.22 -0.11 -0.33 0.19 0.07
18295 47.9.15 -0.17 -0.63 -0.01 -0.13 -0.19 -0.05 0.04 -0.18 -0.17 0.22 -0.35 -0.63 0.10 0.03
18333 45.10.13 -0.03 -0.39 0.04 0.06 0.25 0.05 0.01 0.02 0.07 0.15 0.10 0.12 -0.04 0.61
18339 45.10.19 -0.03 -0.48 0.04 -0.04 -0.11 0.08 0.02 -0.08 -0.12 0.21 -0.09 -0.28 0.24 0.08
18341 46.10.1 -0.05 -0.76 0.10 -0.06 -0.10 -0.48 0.02 0.15 0.02 0.15 0.15 -0.33 0.65 0.01
18379 47.10.19 -0.32 -0.71 -0.08 0.03 -0.17 -0.18 0.02 -0.26 -0.25 0.14 -0.33 -0.47 0.03 0.21
18380 47.10.20 -0.21 -0.62 -0.12 -0.19 -0.03 -0.38 0.04 -0.25 -0.15 0.15 -0.20 -0.44 0.18 0.04
18411 45.11.11 -0.06 -1.19 0.13 -0.17 -0.25 -0.33 0.00 -0.34 -0.38 0.07 -0.58 -0.80 0.09 0.06
18430 46.11.10 -0.30 -0.85 -0.16 -0.18 -0.34 -0.19 0.05 -0.26 -0.31 0.16 -0.39 -0.55 0.04 0.11
18441 47.11.1 -0.06 -0.75 0.02 0.02 -0.03 0.10 0.04 0.06 0.09 0.47 0.20 -0.31 0.18 0.38
18451 47.11.11 -0.27 -1.24 -0.61 -0.58 -0.47 -0.54 0.03 -0.13 -0.28 -0.09 -0.59 -0.75 -0.24 0.04
18473 48.11.13 -0.25 -1.50 -0.48 -0.51 -0.38 -0.53 0.01 -0.90 -0.52 -0.15 -0.33 -0.70 0.02 0.04
18512 46.12.12 -0.63 -0.18 -2.24 -0.76 1.33 -0.58 0.03 -1.15 -0.25 -0.35 -0.38 1.04 1.18 0.61
18599 46.13.19 1.22 0.75 0.79 1.66 2.90 0.01 4.07 1.32 0.35 -0.04 -1.56 0.18
18614 47.13.14 -0.09 -0.53 -0.02 -0.05 -0.16 -0.08 0.05 -0.12 -0.13 0.15 -0.18 -0.39 0.02 0.08
18648 45.14.8 -0.20 -2.06 -0.06 -0.18 -0.22 0.43 0.01 0.19 -0.04 0.33 -0.14 -2.54 -0.34 0.20
18668 46.14.8 0.21 0.72 -0.36 -0.23 -0.11 -0.10 0.02 0.55 0.40 -0.05 0.80 -0.54 -1.05 0.00
18758 46.15.18 -0.05 0.30 0.04 0.25 -0.01 0.00 0.03 -0.07 -0.04 0.02 0.15 0.26 -0.05 0.01
18780 47.15.20 -0.51 -0.05 0.02 -0.03 -0.07 -0.13 0.00 -0.40 -0.11 -0.01 0.40 0.30 0.20 0.00
18813 45.16.13 -0.02 -0.74 0.12 0.08 -0.08 0.05 0.03 0.03 -0.10 0.35 0.09 -0.44 0.20 0.19
18820 45.16.20 -0.18 -0.47 0.05 -0.04 -0.13 -0.05 0.04 -0.10 -0.13 0.28 -0.22 -0.38 0.02 0.09
18825 46.16.5 -0.07 -0.48 0.11 0.01 -0.06 0.05 0.04 -0.10 0.04 0.26 -0.08 -0.31 0.19 0.36
18917 46.17.17 -0.01 1.21 0.43 0.79 0.56 1.61 0.03 0.02 0.08 -0.02 1.01 -1.00 -1.41 0.15
19025 48.18.5 -0.34 -0.39 -1.27 0.48 -0.57 0.08 0.02 -0.37 0.06 0.46 -0.43 -0.45 -0.41 0.71










Time points with CORT 6 
CHX treated or Control groups 2 
Replicates 4 
Total spots on array 19200 
Unique cDNA clones on array 14053 
Total arrays 48 
Total Dyes (Sample and 
Reference pool) 
2 
Total data points 1,843,200 
Spots with significant difference 
between any two time points 
(p<0.05) in the absence of CHX 
457 
Spots with at least half of 
Observations in absence of CHX 
(n≥12) 
388 
Spots with less than a 2-fold 
Effect 251 
Genes Induced Early (In presence 
of CHX) 
51 (13) 
Genes Induced Late (In presence 
of CHX) 20 (9) 
Genes Repressed Early (In 
presence of CHX) 52 (12) 




Table 4.3. Number of transcripts that were either induced early, induced late, repressed 
arly, repressed late, or showed no significant effect across at either time point during the 










































igure 4.2. Distribution of transcripts in e11 chicken pituitary cells during a 24 hr culture 









first affected by CORT at the particular time points.  Open bars represent transcripts that
were ≥2-fold increased in the presence of CORT.  Black bars represent transcripts that 
were ≥2-fold down regulated in the presence of 10-9 M C
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      To verify the data obtained from the microarray, qRT-PCR analysis was performed 
n genes from each gene expression category and the results shown in figure 4.3.  The 
enes that we verified for the no significant effect category are Cytochrome c oxidase 
subunit VIc (CCO) and SMARCD1 protein (SMARCD1).  Cytochrome c oxidase is the 
rminal enzyme of the mitochondrial electron transfer chain and is composed of 10 to 13 
bunits i
WI/SNF-related, matrix-associated, actin-dependent regulators of chromatin protein 
mily164.  LSM7 and PLEKHB1 are two of the transcripts that we verified for genes 
elonging to our repressed early category.  LSM7 is a member of the eukaryotic Sm and 
m-like (LSm) U6 small nuclear RNA associated protein group.  These proteins associate 
ith RNA to form the core domain of the ribonucleoprotein particles involved in a 
ariety of RNA processing events including mRNA degradation, replication of telomeres, 
nd pre-mRNA splicing165.    Pleckstrin homology domain containing, family B 
vectins) member 1 (PLEKHB1) belongs to a group of proteins that have so called 
leckstrin homology (PH) domains.   PH domains are only found in eukaryotes and 
ossess a variety of functions that allow proteins with this domain to be involved in 
rocesses such as regulating the actin of the cytoskeleton, AP1 regulation, apoptosis, and 
uscle differentiation166-168 . Genes that were repressed late were next verified by qRT-
CR.  Two genes belonging to that category were assayed.  The first transcript is CEPU-
e alpha 2 isoform (CEPU) which belongs to the IgLON family, which is a subfamily of 





















neuronal guidance and have been studied in chick embryos170, 171.  The 17 kD fetal brain
protein (FBP) is a product of the chromosome 9 open reading frame 19 gene.  FBP 
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contains a  SCP-like extracellular protein domain that is found in proteins such as human
glioma pathogenesis-related protein (GliPR), the human testis specific glycoprotein 
(TPX-1), and several other extracellular proteins from rodents (SCP), insects venom 








172.  The induced late 
category was validated with Peripheral myelin protein 22 a (PMP22a) and 
SUMO1/sentrin/SMT3 specific peptidase 2 (SUMO2).  PMP22a is a tetraspan mem
glycoprotein whose mutated form is associated with hereditary demyelinating 
neuropathies173, 174, while SUMO2 is a small ubiquitin-like protein that covalently 
conjugates to other proteins and is involved in protein/protein interactions, intracellular 
localization, and prevents some of its binding-targets from ubiquitin-dependent 
degradation175.  Interestingly, SUMO2 has been shown to interact with the MR and 
GR176.  The last category that we validated entailed those genes who induction occurred 
early (within 3 hrs).  qRT-PCR validated two genes in this category, Semaphorin
precursor (SEMA7A) and Notch homolog 2 (NOTCH). SEMA7A is a member of a l
protein family involved in axon guidance signaling177, while NOTCH is a product of
gene that encodes a conserved family of receptors that influence developmental fate o
various cell lineages in many species, including chickens178.  As figure 4.3 shows, gene 













































































































































































































































































































































































































































































































Figure 4.3.  Comparison of the microarray analysis (open bars) of anterior pituitary 
xpression levels for 4 different categories of gene expression with results from 
uantitative real-time reverse-transcription PCR (qRT-PCR) analysis (black bars) on the 
me genes.  Genes from the microarray analysis were put into 1 of 4 categories: No 
ffect, Repressed Early, Repressed Late, Induced Late, and Induced Early.  Levels of the 
alized to levels of beta-actin mRNA, and results are expressed 
lative to the highest expression level for each technique.  Results are presented for 
ytochrome c Oxidase (CCO), SMARCD1 protein (SMARCD1), LSM7 homolog 
SM7), Pleckstrin homology domain containing family B member 1 (PLEKHB1), 
EPU gene (CEPU), 17kD fetal brain protein (FBP), Peripheral myelin protein 22 a 
MP22a), SUMO1/sentrin/SMT3 specific peptidase 2 (SUMO2) , Semaphorin 7A 
recursor (SEMA7A), and Notch homolog 2 (NOTCH) . The qRT-PCR analysis for all 
enes was conducted on amplified RNA.  Values within a given technique with an 
sterisk are significantly different from control (0 hr) (p ≤ 0.05, n=4).  
 
   As stated above, our hypothesis is that CORT induces the synthesis of one or more 
roteins and then these protein(s) initiate GH mRNA production.  The results from figure 
.1 show that GH mRNA is induced significantly within 3 h of CORT treatment.  In 
ddition, we noticed a slight but significant increase in GH mRNA within 1.5 hr.  Given 
ese 2 observations we next theorized that our candidate gene(s) must be up-regulated in 
sponse to CORT within 1.5 hr.  In addition, our candidate gene(s) must also be a direct 
rget of CORT, meaning that it must be induced in the presence of cyclocheximide 
HX).  Table 4.3 shows that 51 transcripts fall into the category of being induced early 
 response to CORT.  Of these 51, only 13 showed at least a 2-fold induction in the 
resence of CHX.  These direct early inducted transcripts are listed in table 4.4.  The 
entities of 2 of these transcripts are presently unknown.  Interestingly the unknown 
anscript corresponding to spot 1 on our microarray chip has the 2nd highest fold 
duction of the directly induced CORT genes.  However, we could not validate this 
































induction on our microarray was the scavenger receptor cysteine-rich type 1 protein.
This receptor belongs to the scavenger receptor cysteine-rich superfamily (SRCR-SF), 
whose members are a highly conserved group of membrane and/or secreted proteins 
related to the innate and adaptive immune system
  
 
Spot Gene Name Fold induction 
179.  Unfortunately, induction of this
transcript could not be verified with qRT-PCR as well (data not shown).   
 
 
1 Unknown 13 
105 ibitory protein 2 Cellular FLICE-like inhlong form 
309 P450 (cytochrome) oxidoreductase 2 
2822 FK506 binding protein 5 2 
2862 Semaphorin 7A precursor 2 
3408 RAS, dexamethasone-induced 1 15 
5047 Ras-dva small GTPase 5 
5048 Unknown 2 
5050 Scavenger-receptor protein 20 
5088 FK506-binding protein 5 4 
8797 Unknown 3 
9246 2 Mitogen-activated protein kinase-activated protein kinase 3 
15282 2 Pyruvate dehydrogenase kinase-like protein 
 
 






     To aid us identifying potential candidate genes, we undertook a clustering method t
group genes based on their expression profiles during their 24 hr period.  Because we 
only interested in expression levels compared to the basal time point and not differenc
that may be observed between the other time points (i.e., 3 hr vs. 6 hr, 6 hr vs. 12 hr, 12




 analysis and 
ierarchical clustering.  To cluster our transcripts, we compared the background corrected 
y3/Cy5 ratios of our control time point (0 hr) to every other time point (i.e., 0 hr vs. 1.5 
hr, 0 hr vs. 3 r vs. 6 hr, 0 hr vs  hr vs. 24 hr) and de ed the levels 
of induction/repression with the following formula (Cy3/Cy5 ratio of 0 hr – Cy3/Cy5 
ratio of sample time point).  If the difference was ≤ -.99, that correlated to a 2-fold 
induction (C  r nd that particular time interval was 
categorized a ce 9, that correlate  a 2-fold 
decrease or r io e interval was categorized as repressed 
(DOWN).  If ff .99, then that time interval was 
perceived as having no significant effect (NA).  With 5 possible time intervals, 3 possible 
outcomes in each tim ssible different combinations totaled 
243.  Out of those 243 possible combinations, only 58 had at least one 1 gene in its 
cluster.  Because we theorized that our candidate gene must be significantly affected 
within 1.5 hr, those clusters who had no significant effect between 0 and 1.5 hr could be 
eliminated.  That left us with 27 possible clusters, whose expression profiles and the 
number of genes in the cluster is shown in table 4.5.   
      
      
h
C
 hr, 0 h . 12 hr, and 0 termin
y3/Cy5 atios are on a log2 scale) a
s indu d (UP).  If the difference was ≥ .9 d to
epress n, and that particular tim
 the di erence was between -.99 and 
e interval, the number of po
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CLUSTER 0-1.5 0-3 0-6 0-12 0-24 # OF GENES
83 UP NA NA NA UP 3
86 UP NA NA UP UP 1
95 UP NA UP UP UP 1
101 UP NA DOWN NA UP 1
109 UP UP NA NA NA 1
112 UP UP NA UP NA 1
113 UP UP NA UP UP 1
118 UP UP UP NA NA 2
119 UP UP UP NA UP 1
121 UP UP UP UP NA 1
122 UP UP UP UP UP 5
136 UP DOWN NA NA NA 4
137 UP DOWN NA NA UP 1
140 UP DOWN NA UP UP 1
149 UP DOWN UP UP UP 1
159 UP DOWN DOWN UP DOWN 1
169 DOWN NA NA DOWN NA 1
181 DOWN NA DOWN NA NA 1
241 DOWN DOWN DOWN DOWN NA 1
82 UP NA NA NA NA 16
85 UP NA NA UP NA 1
92 UP NA UP NA UP 1
142 UP DOWN NA DOWN NA 1
154 UP DOWN DOWN NA NA 1
163 DOWN NA NA NA NA 21
172 DOWN NA UP NA NA 1





Genes were clustered into one of out 243 possible expression profiles according to the
time point comparison (0 – 1.5 hr, 0 – 3hr, 0 – 6 hr, 0 – 12 hr, and 0 -24 hr), the 
affected, NA), exhibit at least a 2-fold increase (UP), or exhibit at least a 2-fold decre




Table 4.5.  Clustering of genes into expression profiles across the 24 hr culture period.  
ir 
expression levels relative to control (0 hr) from the microarray analysis.  During each 
expression levels of genes could either show no 2 fold difference from the control (Not 
ase 
(DOWN) in relative expression levels.  The table shows 27 categories in which there was 
ls during the first 90 minutes of 





     As seen in figure 4.1, expression levels of GH remain elevated throughout the 24 hr 
culture period.  Noticeably, one of our clusters (Cluster 122) contains 5 transcripts whose 
expression levels remain elevated throughout the 24 hr culture period.  Two of these 
transcripts represent members of the Ras superfamily of signal transduction proteins.  
RAS, dexamethasone-induced 1 (also known as Dexras1) was originally identified in 
1998 as a  gene in a murine corticotroph cell line (AtT-20) that was rapidly induced in 
response to glucocorticoid treatment133.  Dexras1 has been shown to have a variety of 
possible functions such as a suppressor of G-protein signaling downstream of ligand 
binding135, 136 and as a protein-binding partner for CAPON, which is a protein known to 
associate with neuronal nitric oxide synthase137.  The other ras protein is Ras-dva small 
GTPase, which has been shown to be an essential component of the signaling network 
that patterns the early anterior neural plate and the adjacent ectoderm in Xenopus laevis 
embryos180.  In addition to these proteins being involved in signal transduction pathways, 
these two genes are ideal candidates because previous research in our laboratory has 
own that that the Ras inhibitor manumycin suppressed CORT stimulated increases in 
H mRNA levels120.  The third transcript in this cluster is FK506-binding protein 5 
KBP5).  FKBP5 is an immunophilin that binds FK506, and is an ideal candidate 
ector.  The fourth transcript is corresponds to spot 2644 on our microarray and is an 




because it has been shown to be involved in nuclear translocation of the glucocorticoid 
receptor (GR)181, and FK506 has been shown to stimulate GH release from rat 
somatotrophs182.  The cDNA clone of FKBP5 from our cDNA library is not of full length 





eliminated from further analysis.  The last transcript in this category is Scavenger 
receptor protein (SR), which is a membrane receptor that binds lipoproteins and are 
involved in their uptake into cells183, and SR has been characterized in chickens184.  
Unfortunately, we could no verify the expression levels of SR with qRT-PCR. 
    We also decided to choose a transcript that was directly repressed by CORT within 
to support the hypothesis that CORT treatment can repress the expression of an inhibito
that suppresses GH mRNA production.  One interesting candidate that fit this profile w
Prostaglandin-D synthase (PGDS).  PGDS synthase catalyzes the isomerization of 
Prostaglandin H2, a common precursor of various prostanoids, to produce Prostaglandin-
D 2 (PGD2) in the presence of sulfhydryl compounds.  PGDS is considered to be a dual-
function protein; it acts as a PGD2-producing enzyme and also as a lipophilic ligand-









185. The fact that PGDS can bind thyroids is of particular interest to us 
because previous research in our laboratory has shown that treatment of chick embryo
pituitary cells with T3 or T4 alone had negligible effects on somatotroph abundance in 
vitro113.  On the other hand, the combination of the thyroid hormones and CORT were 
able to augment GH cell numbers above that found with CORT alone. 
     Before we could proceed with further analysis of our candidate genes (Dexras1, 
PGDS, Ras-dva), we had to verify the microarray analysis of these genes by qR
As shown in figure 4.4, expression levels of both Dexras1 and Ras-dva are significantly 
increased within 1.5 hr in both techniques.  Microarray analysis of PGDS shows that its
expression levels doesn’t become significantly decreased until 3 hr after CORT 
treatment.   However, qRT-PCR shows that PGDS expression levels are significa
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repressed within 90 min.  Despite this discrepancy, both techniques show that PGD




quantitative real-time reverse-transcription PCR (qRT-PCR) analysis (black bars) 
were normalized to levels of beta-actin mRNA, and results are expressed relative to 0 hr 
A.  

















Figure 4.4.  Comparison of the microarray analysis results (open bars) with results from 
Dexras1, Ras-dva, and Prostaglandin-D synthase (PDS2).  Levels of the analyzed genes 
time point. The qRT-PCR analysis for all genes was conducted on amplified RN
another (p ≤ 0.05, n=4).  
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Effect of overexpression of candidate genes on GH mRNA 
     If the candidate gene directly induces GH mRNA, then overexpression of that gene 
ould lead to an increase in GH mRNA even in the absence of CORT.  Furthermore, if 
verexpression of a ay 
lay a role in CORT induction of GH mRNA.  All of the cDNAs in our library are in a 
ukaryotic expression vector, pCMV-Sport6.1.  The clones for the candidate genes that 
e have chosen (Dexras1, PGDS, and Ras-dva) contain the full length cDNA for their 
spective genes, and as a result no further cloning was necessary to express the gene 
roduct.  e11 pituitary cells were transfected with either an empty pCMV-Sport6.1 
ector, or this vector containing Dexras1, PGDS, or Ras-dva.  A Golgi-targeted GFP-
xpressing plasmid was co-transfected to facilitate isolation of transfected cells.  After 24 
rs, one well from each transfection group was treated with CORT for 18 h, while the 
ther well of the same transfected group was left untreated.  After the 18 hr incubation 
eriod, the cells were sorted into GFP+ and GFP- cell groups.  RNA was then extracted 
om only those cells that were GFP+, and qRT-PCR analysis was performed to determine 
lative mRNA levels.  A result from one FACS experiment is shown in figure 4.5.  Cells 
at are positive for GFP are contained within the large rectangle on the right side of each 
raph, while GFP- negative cells are located outside of the rectangle.   The top graph 
presents cells that were non-transfected, while the bottom graph represents cells 
t 
sh
















transfected with GFP and Dexras1.  As figure 4.5 illustrates, the percentage of fluorescen
cells increases (~18%) dramatically in the culture transfected with the GFP expression 
























Figure 4.5.  FACS analysis of cells transfected with Dexras1 and a Golgi-targeted GFP-
bottom represents cells transfected with Dexras1 and GFP. 
 
      
expressing plasmid.  The top panel represents cells that were non-transfected and the 
 Fluorescent cells are 
contained in a rectangle on the right side of each graph, and non-fluorescent cells are 
cated outside of the rectangle. 




     Table 4.5 shows that the genes transfected into the e11 pituitary cells are indeed being 
ver-exp
, or Ras-dva did not cause an elevated amount of GH mRNA in e11 
 the absence of CORT, meaning that none of these genes can directly 
imulate GH mRNA production.  However, there was a significant increase in GH 
RNA in cells that were transfected with the Dexras1 plasmid in the presence of CORT, 
lative to cells transfected with the empty vector and treated with CORT.  This 
bservation shows that Dexras1 can act synergistically with CORT to increase GH 
RNA levels in e11 pituitary cells.  Perhaps there is an additional unknown gene that 
ORT induces along with Dexras1 that allows the increase in GH mRNA in response to 
so tested what effect overexpression of our candidate genes would have 
n two other pituitary hormones, prolactin and pro-opiomelanocortin (POMC).  
owever, transfecting with our candidate genes had no significant effect on the levels of 
RNA for transcription of these genes.  In addition, we chose two other genes that were 
directly induced late in response to CORT to see if overexpression of our candidate 
enes affected their expression levels.  The two additional genes that we chose to analyze 
ere Selenoprotein I and Inhibitor of apoptosis 3 (IAP3).  The function of Selenoprotein 
is currently unknown but has been isolated in a chicken bursal lymphocyte cDNA 
brary186.  IAP3 is, as its name suggests, an anti-apoptotic factor whose expression was 
und elevated during the differentiation of the developing chick lens187.  As the graph in 



















figure 4.7 shows, overexpression of our candidate genes had no effect on Selenoprotein 





















Table 4.6.  Confirmation of overexpression of transfected genes.  Dispersed e11 pitu
pCMV-Sport6.1 vector, or the same vector containing cDNAs for chicken Dexras1, 














cells were cultured in serum-free media and then transfected with either an empty 
PGDS, or Ras-dva, along with a Golgi-targeted GFP-expressing plasmid.  After 24 hrs, 
identical well was left untreated.  After the 18 hr incubation period, the cells were 
from only those cells that were GFP  and qRT-PCR analysis was performed to determine 
d to levels of beta-
actin mRNA, and results are expressed relative to cells transfected with empty pCMV-
port6.1 vector with no CORT treatment. 
 
Prostaglandin-D Synthase Sport6.1 No 1 ± 0.0
Dexras1 Dexras1 No 119.9 ± 25.5
Ras-dva Dexras1 Yes 3.2 ± 1.9
Ras-dva PGDS Yes 3.3 ± 2.3
Ras-dva Ras-dva Yes 600.3 ± 339.9
-9 M) for 18 h while an 
retrypsinized and sorted into GFP+ and GFP- cell groups.  Finally, RNA was extracted 
+
relative mRNA levels.  Levels of the analyzed genes were normalize
mRNA quantified Gene transfected CORT Treated Fold Expression ± SEM
Prostaglandin-D Synthase Dexras1 No .7 ± .2
Prostaglandin-D Synthase PGDS Yes 261.7 ± 115.5
Prostaglandin-D Synthase PGDS No 380.1 ± 126.3
Prostaglandin-D Synthase Ras-dva Yes 4 ± 2.3
Prostaglandin-D Synthase Ras-dva No .6 ± .2
Prostaglandin-D Synthase Sport6.1 Yes .9 ± .5
Dexras1 Dexras1 Yes 131 ± 30.0
Dexras1 PGDS Yes .6 ± .3
Dexras1 PGDS No .5 ± .1
Dexras1 Ras-dva Yes .5 ± .1
Dexras1 Ras-dva No .7 ± .1
Dexras1 Sport6.1 Yes 4.8 ± 1.5
Dexras1 Sport6.1 No 1 ± 0.0
Ras-dva Dexras1 No 1.8 ± 0.4
Ras-dva PGDS No 1.5 ± 0.2
Ras-dva Ras-dva No 248.6 ± 106.2
Ras-dva Sport6.1 Yes 1.4 ± 0.5
Ras-dva Sport6.1 No 1 ± 0.0

























ith different letters are significantly different 




levels.  Dispersed e11 pituitary cells were cultured in serum-free media and then 
transfected with either an empty pCMV-Sport6.1 vector (SPORT), or Dexras1 (DR
PGDS (PDS), or Ras-dva (DVA) plasmid along with a Golgi-targeted GFP-expressin
plasmid.  After 24 hrs, one well from each transfection group was treated with CORT 
(10-9 M) (black bars) for 18 h while the other was left untreated (open bars).  After the 18 
hr incubation period, the cells were retrypsinized and sorted into GFP+ and GFP- ce
groups.  Finally, RNA was extracted from only those cells that were GFP+ and qRT-PC
analysis was performed to determine relative mRNA levels of Growth Hormone, POMC, 
and Prolactin.  Levels of the analyzed genes were normalized to levels of beta-actin 
mRNA, and results are expressed relative to cells transfected with empty pCMV-Sport6


























Figure 4.7.  Effect of overexpression of candidate genes on CORT induced genes.  
Dispersed e11 pituitary cells were cultured in serum-free media and then transfected w
either an empty pCMV-Sport6.1 vector (SPORT), or Dexras1 (DR), PGDS (PDS), or 
Ras-dva (DVA) plasmid along with a Golgi-targeted GFP-expressing plasmid.  After 24
hrs, one well from each transfection group was treated with CORT (10-9 M) (black bars) 
for 18 h while the other was left untreated (open bars).  After the 18 hr incubation period, 
the cells were retrypsinized and sorted into GFP+ and GFP- cell groups.  Finally, RNA 
was extracted from only those cells that were GFP+ and qRT-PCR analysis was 
performed to determine relative mRNA levels of Selenoprotein, and Inhibitor of 
Apoptosis 3 (IAP3).  Levels of the analyzed genes were normalized to levels of beta-actin 
mRNA, and results are expressed relative to cells transfected with empty pCMV-Sport6.1 
vector with no CORT treatment.  Values with different letters are significantly different 




     We have used a chicken DEL-MAR DNA microarray to 
assess global gene expression in chicken em  pituitary cells treated with 
CORT. Our custom mi m the 
neuroendocrine system , the liver, adipose tissue, and skeletal 
muscle.  It is estim
genes188, so our mi e. 
     Glucocorticoids are capable of induci on in both fetal rats 
and chicken embryos189 s blocks glucocorticoid induction 
of GH mRNA in both chickens ediary protein is 
quired for GH expression. The aim of the present study was to identify genes that are 
volved in CORT induction of GH mRNA expression.   
 of our study was to identify possible genes that may regulate CORT 
duction of GH, we had to establish the time course of CORT induction of GH mRNA, 
ecause any gene involved would have to be induced before or coincident GH.  We 
ultured e11 pituitary cells with CHX pretreatment then CORT or just with CORT alone.  
s the results from figure 4.1 show, GH is significantly induced within 90 minutes and 
n 
14K Integrated Systems c
bryonic anterior
croarray contains 14,053 cDNAs assembled fro
, the reproductive system
ated that the chicken genome contains between 20,000 to 23,000 
croarray covers more than half of the chicken genom
ng somatotroph differentiati
.   Inhibition of protein synthesi
120 and rats115, entailing that an interm
re
in





continues to rise significantly until 3 hr, where the levels remain statistically similar 
between 3 and 24 hr but stay well above the levels at the 0 hr time point.  As we stated 
earlier, CHX treatment blocks CORT induction of GH mRNA, and the results from 
figure 4.1 confirm that.  Glucocorticoids have to been shown to increase gene expressio
even earlier than 90 minutes.  For example Dexamethasone can increase the dual-
specificity MAPK phosphatases MKP-1 10-fold within 30 minutes190.  However, rapid 
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glucocorticoids do have some nongenomic effects such as regulating mRNA stability19
192.  
     The microarray analysis that we performed was done on 19,200 genes, of 
14,053 represent unique chicken cDNAs.  Of those 14, 053 cDNAs only 388 showed a 
significant difference in expression between any two time points (p<0.05) and were 
observed in at least half of the potential observations (n ≤ 12; maximum = 24).  The use 
of a rich time-series design for the examination of hormone effects using high-throughpu
methods such as microarrays provides the advantages that multiple independent 
measurements taken over relatively short time intervals abrogate the need for 
independent confirmation of gene regulation necessary with single-point studies, and 
provides a definitive analysis of the pattern of regulation t
be obscured by single time point studies.  However, the extremely large datasets 
generated by such a design provides challenges in analysis.  As a result, we did not 
perform common clustering analysis methods, such as SOMS and hierarchical cluste
but instead group genes based on the magnitude of expression and time of expression.  
We first categorized the gene expression data into 5 groups, (1) Genes that were induced
at least 2-fold within 3 hr were considered Induced early; (2) Genes that were repress
at least 2-fold within 3 hr were considered repressed early; (3) Genes that were induced 
late (after 3 hrs); (4) Genes that were repressed late; and (5) Genes that showed no 2-
induction/repression.  As seen in table 4.3, the majority of the 388 significant genes 
belong to the category 5, 251 genes.  As can been seen from table 4.3 and figure 4.
majority of the genes that were regulated by CORT (either directly or indirectly) were 
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regulated relatively early (within 3 hr).  This finding is consistent with the lipophilic 
nature of steroid hormones such as glucocorticoids, which are able to diffuse easily into 




6 hr, 0 
es 
d.  
immediate and brief compared to protein hormones.  On the other hand, protein 
hormones have into bind to a membrane receptor and initiate a signaling transduction 
cascade to affect gene transcription, and require an energy-requiring process to be ab
enter the cell.  Of the 388 genes that we categorized, only 51 were induced early (i.e., 
within 3 hr) and of those 51 only 13 were induced in the presence of CHX.  We also had 
to account for genes who even though were directly induced early in response to 
might exhibit an biphasic expression profile that would be inconsistent with th
expression profile seen with GH during the 24 hr culture period.  To cover for this 
possibility, we performed a cluster analysis were genes were clustered according to their 
expression levels at various time intervals (i.e., 0 hr to 1.5 hr, 0 hr to 3 hr, 0 hr to 
hr to 12 hr, 0 to 24 hr).  Due to the fact we had 5 time intervals and 3 possible outcom
in each interval (up-regulated, down-regulated, or no 2-fold difference) this gave us 243 
different possible combinations.  Because our candidate gene(s) had to be significantly 
affected within 90 min, this allowed us to eliminate the majority of the 243 possible 
expression patterns until we were left with 27 clusters that had at least one gene in them 
(Table 4.5).  Of these 27 clusters, cluster 122 was the most interesting.  This was so 
because its expression profile was consistent with the expression profile of GH, meaning 
gene expression levels remained above basal (0 hr) throughout the 24 hr culture perio
Before we could proceed with further analysis, the results obtained from the microarray 
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had to be verified by another technique, in this case qRT-PCRT.  As the results showe
from figure 4.3, the two methods are decidedly similar in measuring gene expression. 
     As mentioned previously, our microarray analysis identified 13 transcripts that w
directly induced by CORT (shown in table 4.4), and of those 13, 4 occupied clus
Two of the genes in cluster 122 are Ras proteins, Dexras1 and Ras-dva.  These two gen
made ideal candidates because we have previously shown that the ras inhibitor 
manumycin blocks CORT induction of GH mRNA
d 
ere 








CORT or with no treatment.  Confirmation that the plasmids were being transcribed is 
120.  Another transcript in this cluste
represents FK506 binding protein 5 (FKBP5), which is an immunophilin that binds 
FK506.  In addition to FKBP5 being directly and rapidly induced by CORT, it is of 
particular interest because it is involved in nuclear translocation of the glucocorti
receptor (GR)181 and FK506 can incite GH release from rat somatotrophs182.  Howe
the cDNA clone from our library does not contain the full length sequence.  We choose a 
3rd gene, prostaglandin-D synthase (PGDS), because it was directly repressed in response
to CORT as wells as the fact that this protein binds thyroid hormones.  This was of 
interest because we have previously shown that treatment of chick embryonic pituitary 
cells with T3 or T4 alone had minor effects on somatotroph abundance in vitro113.  
Conversely, the combination of CORT and the thyroid hormones were able to increas
the number of somatotrophs above that found with just CORT alone.   
     All of the cDNAs in our library are in a eukaryotic expression vector, pCMV-
Sport6.1, and the clones for our 3 candidate genes (Dexras1, PGDS, and Ras-dva) contain
the full length cDNA.  We transfected into e11 pituitary cells the plasmids for Dexras1, 
PGDS, and Ras-dva, and then we treated the cells either for 18 hrs in the presence of 
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shown in table 4.6.  None of the genes that we tested had any direct effect on GH mRNA




     Currently, we are in the process of cloning additional candidate genes into expression 
to ascertain if any of these genes are involved in CORT induction GH.  Genes such as 
FKBP5 will be of particular interest because of the previous findings of its involvement 
in GR translocation and GH release from rat somatotrophs.  FKBP5, Ras-dva, and 
Dexras1 were also found to be up-regulated in a developmental study in our lab using 
another of our custom microarrays .  In that study, changes in gene expression were 
assayed with a 5K array from e10 to e17 of chicken embryonic development.  During 
time period of e12 to e14, there was a significant increase in expression levels of those 3 
genes.  This finding is consistent with the rise in serum glucocorticoids that occurs in the 
chick embryo on e14 .  Future work will also attempt to determine the exact role of 
Dexras1.  For example investigators could use either siRNA or antisense RNA to knock-
down Dexras1 transcript levels and see what effect this would have on GH production.  
Because Dexras1 is a member of the Ras superfamily, it is most likely involved in a 
number of different signal transduction pathways and may have numerous functions in 
the cell.  Indeed, it has been shown to have a very diverse range of tasks.   Dexras1 has 
been shown to function as a ligand-independent activator of G-proteins and it may act to 
GH mRNA. It is possible that CORT induces another gene in addition to Dexras1 and 
that these two induce GH mRNA.  We also tested to see if our genes had any direct effect 
on the genes of two other pituitary hormones, prolactin and POMC, and two CORT 
regulated genes, Selenoprotein I and IAP3.  However, overexpression of our can





suppress G-protein signaling downstream of ligand binding135, 136.  Last but not least, 
Dexras1/AGS1 might have a potential function as a mediator of glucocorticoid negative 
feedback regulation of ACTH secretion from pituitary corticotrophs.  Dexras1/AGS1 is




orm of Dexras1 in AtT-20 cells 
suppressed cAMP-stimulated secretion of transiently expressed growth hormone, 
corroborating the perception that Dexras1/AGS1 might work to impede regulated 






133, 138.  In AtT-20 cells, this induction is glucocorticoid-specific, occu
a dose-dependent manner, and appears mediated at the level of gene transcription133, 139.  
What's more, the expression of a constitutively active f
138
     Based on the available data, we have proposed 2 possible mechanisms by which
Dexras1 could act in conjunction with the unknown CORT induced production to 
stimulate GH mRNA production (Figure 4.8).  The first example we called the “Genom
model”, and it involves the activated GR binding to the promoter elements of CORT 
responsive genes and influencing transcription.  In the “Genomic model”, CORT diffuses
into the cell where it binds to and activates the GR.  The activated GR then initiates 
transcription of both Dexras1 and the unknown gene.  Afterwards both Dexras1 and th
unknown protein act synergistically to stimulate GH mRNA production.  In the 
“Nongenomic model”, CORT regulates Dexras1 protein levels in one of two ways.  
CORT can 1) increase the stability of Dexras1 mRNA leading to an increase in 
translation of Dexras1 mRNA.  Glucocorticoids have been shown to affect the mRNA 
stability of various genes193-195.  Or 2) CORT/GR can directly activate the Dexras1 
protein through protein/protein interaction.  In various experimental systems GR has been
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reported to associate with proteins involved in other signaling pathways such as NF-
κB196, 197, STAT3198, and STAT5199.   In the end result of either “nongenomic” 
mechanism, Dexras1 can then initiate various signal transduction cascades which leads to
the transcription and translation of an unknown protein(s) and this unknown protein(s) 
stimulates the transcription of the GH gene.  The unknown protein(s) is most likely 
regulated by the PI3K, p38 MAPK, MEK 1/2, and Ras signal transduction pathways 
because previous research in our lab have shown that inhibitors of these pathways blocks 
CORT induction of GH
 






































Figure 4.8.  Possible mode of action of Dexras1 on CORT induced GH mRNA 
expression.  Genomic Model (top): Glucocorticoids (GCs) freely diffuse through the cell 
me
ctivated GR can then induces the transcription of an unknown gene leading to 
production of its protein (UG), and the activated GR can then either induce the 
xpression of Dexras1 by binding to cis-elements located in its promoter or activate its 
expression by some unknown trans-mechanisms.  The unknown protein and Dexras1 can 
en act synergistically to induce GH mRNA.  Nongenomic Model (bottom):  GCs again 
freely diffuse through the cell membrane to bind and activate the GR. The activated GR 
an increase Dexras1 protein levels either through increasing mRNA stability of Dexras1 
or activating the Dexras1 protein directly through protein/protein interaction.  The 
ctivated Dexras1 protein can then initiate signal transduction cascades such as the PI3K, 
p38 MAPK, and MEK 1/2 pathway which then stimulates the transcription of an 
nknown gene.  The protein product of the unknown gene can subsequently induce GH 
gene transcription. 
 
   It is still unknown at the present time whether it is necessary for the activated GR to 
ind to the promoter region of Dexras1 in order to stimulate transcription of the gene.  To 
ate, only one functional glucocorticoid response element (GRE) has been discovered in 
 Dexras1 gene.  In a study by Kemppainen et al, a GRE was discovered in the 3’ 
anking region (2.3 kb downstream of poly(A) signal) of the human Dexras1 gene146.  
ased on the present evidence, we can hypothesize that glucocorticoids can stimulate 
exras1 mRNA expression by binding to GREs in cis-elements in the Dexras1 gene or 
ctivate it by some unknown trans-mechanism.  We have proven that glucocorticoids 
ust be able to interact with the GR in order to induce GH mRNA128, but one must also 
onsider the possibility that the mechanism by which the GR induces GH mRNA might 
e independent of its binding to DNA.  GREs have been discovered in the rat and human 
rowth hormone gene95, 201, but to date no functional GRE has been found in the chicken.  
resent work in our laboratory is currently underway to identify a GRE in the chicken 
 























     In conclusion, we used a custom chicken cDNA microarray, the Del-Mar 14K
Integrated Systems Microarray, to analyze global gene expression in the chicken 
embryonic pituitary cells and to identify possible candidate genes that are involv
CORT induction of GH mRNA.  We identified 25 direct targets of CORT that were 
rapidly induced or repressed (within 3 hr) in the presence of CHX.  From these possible 
candidates, we measured the effect of overexpression on GH mRNA of three of the
genes (Dexras1, Ras-dva, and Prostaglandin-D Synthase).  We found that overexp
of these genes had n
 
ed in the 
se 
ression 
o direct effect on GH mRNA, but Dexaras1 was able to act 
nergistically with CORT to induce GH.  We are currently cloning the genes of other 














     The aims of this project were simple in design, although the actual execution o
going to be a major undertaking.  We started the construction of our  DEL-MAR 14K 
Integrated Systems microarray back in 2002 as a consortium project, and at that time
there were no microarray chips available for chicken.  Our hope was to initiate a new era
in the functional genomics of poultry by supplying genomic resources [expressed 
sequence tags (EST) and DNA microarrays] and by investigating global gene expression 
in various target tissues of chickens.  The use of DNA microarrays has been a pr
approach for the discovery of functional genes in several model organisms (i.e., human,
mice, frog, zebrafish, fruit fly, etc.), and our current study has again shown the value






microarrays.   
 
   In the current study we decided to pursue possible candidate genes that might be 
involved in CORT induction of GH mRNA during chicken embryonic development.  In 
addition, we also tried to analyze global gene expression in response to CORT treatment 
ith the hope of possibly identifying new CORT regulated genes.  Without the use of our 
microarray, this project would have taken a lot longer because we would have had to 
pursue genes one at a time and given the fact that there is estimated to be ~20,000 – 
3,000 genes in the chicken genome, needless to say this project would have taken some 
time.  Also, it would have been very difficult to identify genes that might be involved in 
various pathways without being able to analyze global gene expression.  Some of the 
irectly induced early genes that are presented in table 2 have not been shown to be 













nd these genes would have to be significantly up/down-regulated in a 






The fact we showed have shown these genes to be directly regulated by glucocorticoids 
can provide new insights and information into their function, how they are regulated, a
what cellular pathways/processes they could be involved in in chickens, as well as oth
species.   
 
     We chose to analyze gene expression over a 24 hr culture period.  This design would 
have been all right, but we were also pre-treating cells with a protein synthesis inhibito
(CHX) and the deleterious effects of this inhibitor over a 24 hr span make interpreting the
results difficult.  Furthermore, we were looking for possible candidate genes involved
GH induction a
sh
In addition, we might have also tried to analyze gene expression in time points earlie
than 1.5 hr.  For example, we could have substituted the 24 hr time point with a 45 min 
time point.  This earlier time point could have provided some more information on genes 
that are possibly induced by glucocorticoids through a non-genomic pathway.  For 
example, Dexras1 has been shown to be induced within 15 min in AtT-20 cells, and th
time period is probably too short to be the result of the GR binding to DNA and indu
transcription. 
 
     Also in hind site, it would have been better to clone those candidates that weren’t f
length into the Sport 6.1 vector in the beginning.  This would have resulted in all of t
candidate genes in the same expression vector and would have maintained uniformity 
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across all of the candidates in the transfection experiments.  In the end, this would have 
saved valuable time.   
 
     The clustering method that we decided to use was intriguing, especially the fact that 
the most promising candidate genes (Dexras1, Ras-dva, and FKBP5) were all in the same 




stering methods will be of use in the examination of genes involved in the 




time-series microarray experiment will benefit highly from this clustering method.  
Especially if they are using fewer time or data points than we decided to use.   When we 
were using SOMS and hierarchical clustering, the candidate genes that we chose never 
ended up in the same cluster.  SOMS analysis and hiearchical clustering are most likely 
not the most ideal method to use in a time-series design, although there have been 
previous time-series microarray studies that have used SOMS and hiearchical clustering. 
The only limitation with these techniques in a time-series format is that genes that diffe
in expression levels but behave similarly across the 24 hr culture peroid, are usually put 
into different clusters.  In the format that we used in our study, the expression pattern of 
the genes outweigh their expression levels.  The clustering method that we used is a
example of when a very simple method may be more effective than a complicated one.  




     Lastly, the use of a pituitary cell-line would be an invalubable tool in the identificatio
of glucocorticoid-regulated genes invovled in somatotroph differentiation.  We have tri
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in the past to create one, and obviously we did not succeed.  However, the time and effor
that is required to creat
t 
e a cell line would be greatly outweighed by its beneifts.  The use 
f a cell line would not only save time and money in the long run, but would also remove 
 
 and 
     In summary, we used a custom chicken cDNA microarray, the Del-Mar 14K 
Integrated Systems Microarray, to analyze global gene expression in the chicken 
embryonic pituitary cells and to identify possible candidate genes that are involved in the 
CORT induction of GH mRNA.  We detected 25 direct targets of CORT that were 
rapidly induced or repressed (within 3 hr) in the presence of CHX.  From these possible 
25 candidate genes, we measured the effect of overexpression on GH mRNA of three of 
these genes (Dexras1, Ras-dva, and Prostaglandin-D Synthase).  We found that 
overexpression of these genes had no direct effect on GH mRNA, but Dexaras1 was able 
to act synergistically with CORT to induce GH.  We are currently cloning the genes of 
other potential candidates and will determine their effect on GH and other genes as well. 
 
o
the necessity of having to amplify the RNA for microarray analysis or dilute RT samples
in order to be able peform more qRT-PCR analysis.  Even though the use of amplfiied 
RNA in microarray analysis and diluted RT samples has become a common practice, if 
these steps could be eliminated the interpretation of the results would be more direct
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